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ABSTRACT
Originally thought to function only as a scaffold, the extracellular matrix (ECM)
is now understood to provide signals that regulate all aspects of cellular phenotype.
Matricellular proteins are a subset of ECM-related molecules defined by their ability to
modulate interactions between cells and the ECM. Periostin was recently classified as a
matricellular protein based on its expression and function during development and wound
repair. Periostin has been shown to influence cell behavior and collagen fibrillogenesis in
several tissue types. In this study, we examined how periostin expression influences
fibrocyte behavior after dermal injury using periostin null (Pstn −/−) and wild-type (WT)
mice. Both periostin upregulation and fibrocyte infiltration have previously been shown
to accelerate dermal closure after acute injury and to promote excessive scarring in
fibrotic tissues. We found that periostin expression elevates fibrocyte levels in murine
dermal wounds during wound contraction and at late stages of tissue remodeling. This
suggests a novel mechanism by which periostin expression may accelerate the closure of
dermal wounds as reported by other investigators and increase collagen accumulation in
dermal scar tissue as demonstrated in this work. Periostin upregulation was also found to
elevate circulating fibrocyte levels in the blood, suggesting that the peripheral circulation
is a significant source of fibrocytes after dermal injury and that periostin expression
influences fibrocyte behavior outside of the dermal wound bed. In vitro analysis of
fibrocyte migration revealed that periostin expression also increases CXCL12-induced
chemotaxis and integrin-mediated migration on periostin. CXCR4+/collagen type I+
(Col+) fibrocyte levels were also found to be elevated after dermal injury in WT mice
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compared to Pstn −/− mice, providing in vivo evidence indicating that periostin
upregulation promotes fibrocyte participation in the CXCR4/CXCL12 signaling axis.
Evaluation of our findings as well as data presented in previous publications suggests that
periostin expression elevates fibrocyte levels in the dermal wound bed and peripheral
blood by stimulating the fibroblastic differentiation of fibrocyte precursors and/or
increasing the migration of fibrocytes and their precursors into these tissues. Collectively,
the work presented in this dissertation demonstrates a novel role for periostin in
promoting fibrocyte participation in wound repair, and also suggests that therapeutic
strategies aimed at modulating periostin expression may be effective in regulating
fibrocyte contribution to wound closure and tissue fibrosis.
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CHAPTER ONE
INTRODUCTION
1.1

Clinical Significance
Dermal wound healing is a complex process characterized by coordinated cell

activity in response to a milieu of molecular and environmental effectors. The wound
repair process consists of four highly integrated and overlapping phases (hemostasis,
inflammation, proliferation, and remodeling) that ultimately result in the formation of a
fibrotic scar1. Alterations in the normal repair process can lead to significantly worse
outcomes by preventing wound closure (chronic wounds) or by inducing excessive
fibrosis (hypertrophic and keloid scars)2. These complications can ultimately result in
disfigurement, disability due to loss of function, or even death3. The enormous demand
for therapies that promote the closure of non-healing wounds and reduce the appearance
of scars has led to the development of a global market for advanced wound care
treatments exceeding $5 billion annually4. Despite recent innovations in therapeutic
strategies, wound healing complications continue to represent a significant burden to the
healthcare system due to the complexity of the repair process. The development of
improved treatment technologies will require an increase in our understanding of the
physiological processes that govern dermal wound repair.
Though much research has focused on the role of major structural proteins in
wound repair (i.e. collagens, fibronectin, laminins, etc.), increasing attention is being
given to a small group of glycoproteins termed matricellular proteins. Matricellular
proteins do not contribute directly to the structural integrity of ECM elements (fibrils,
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basement membrane)5. Instead they bind to other matrix proteins, cell surface receptors,
and molecules such as proteases and cytokines to modulate cell-matrix interactions and
cell function5. Over the past two decades, the matricellular protein periostin has received
much attention, primarily in the areas of cardiac development, cancer biology, and organ
fibrosis6-8. Research in these fields has shown that periostin expression influences
numerous biological processes, including cell differentiation, proliferation, and
migration, as well as ECM maturation and remodeling.
Upregulation of periostin expression after acute dermal injury was first reported
in 2007 by Jackson-Boeters and colleagues9. Three independent studies exploring the role
of periostin expression in acute dermal repair have since demonstrated that periostin gene
deletion leads to delayed wound closure10-12. By examining the behavior of resident cell
populations, altered wound repair kinetics in Pstn −/− mice were concluded to result from
delayed reepithelialization, decreased wound contraction, and impaired fibroblast
activity. Given the diverse effects of periostin expression on cell behavior in other
systems, it is not surprising that periostin appears to influence multiple stages of dermal
repair. Additionally, exogenous administration of periostin has been demonstrated to
promote wound closure, suggesting that periostin may be a useful target for therapies
aimed at accelerating dermal repair12. On the opposite end of the spectrum, periostin has
also been implicated in dermal fibrosis, with scleroderma skin lesions and hypertrophic
and keloid scars exhibiting increased levels of periostin expression13,14. Despite these
observations, the role of periostin upregulation in ECM maturation and remodeling after
acute dermal injury has not been analyzed.
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Historically, resident fibroblasts have been portrayed as the key cellular effectors
that direct wound contraction and ECM deposition after dermal injury. However, recent
studies suggest that a population of circulating cells, termed fibrocytes, also play a
critical role in these processes. Fibrocytes are a unique subset of collagen-producing
hematopoietic-derived cells that home to sites of injury and participate in wound repair
and fibrosis15. Fibrocytes contribute to the myofibroblast population in injured skin and
have been shown to participate in tissue remodeling through ECM protein production and
matrix metalloproteinase secretion16,17. As a significant source of cytokines, chemokines,
and growth factors, fibrocytes also contribute to autocrine and paracrine signaling in
injured tissues and have been suggested to regulate resident fibroblast activity by
promoting proliferation, migration, myofibroblastic differentiation, and collagen
production18.
As the field of fibrocyte biology advances, a growing body of evidence suggests
that fibrocytes play a critical role in wound repair and fibrotic disease pathogenesis.
Therefore understanding the biological mechanisms that govern fibrocyte activity will be
important for the development of treatment strategies that prevent fibrosis while also
promoting wound repair. Interestingly, fibrocytes appear to promote tissue repair and
fibrosis in many of the disease pathologies that also exhibit periostin upregulation,
including dermal wound healing, keloid and hypertrophic scarring, pulmonary fibrosis,
and interstitial myocardial fibrosis15,18-21. Recently published reports have suggested a
potential link between periostin expression and fibrocyte-facilitated tissue fibrosis in the
lungs and heart22,23. However, this relationship remains ill-defined and, to our knowledge,
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has not been explored in the area of dermal wound healing.

1.2

Project Objective and Specific Aims
The goals of this research project are based on an extensive review of the

literature as well as our lab’s interest in the bone marrow contribution of fibroblast-like
cells to tissue repair. The matricellular functions of periostin in modulating cell-matrix
interactions and cell behavior, as well as the overlapping influences of periostin
expression and fibrocyte infiltration on wound repair and tissue fibrosis suggest periostin
to be a potential regulator of fibrocyte activity during dermal repair. Thus, our overall
objective is to explore how periostin expression influences fibrocyte behavior after
dermal injury. Our over-arching hypothesis is that injury-induced periostin expression
promotes wound closure and scar formation by stimulating the differentiation and/or
engraftment of fibrocytes in dermal wounds. The aims used to complete this project are
outlined below.

Specific Aim I: Identify the effects of periostin expression on the composition and
structural organization of the reparative ECM after dermal injury.
Rationale: The final architecture of the reparative dermal matrix is determined by
interactions between cells, soluble mediators, and ECM proteins. As a matricellular
protein, periostin uniquely functions as a bridge between cells and the surrounding ECM.
However, the functional role of periostin expression in scar formation following acute
dermal injury has not been described. Therefore, histological staining and
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immunofluorescence labeling were used to visualize gross tissue morphology and the
deposition of important ECM proteins after dermal injury in Pstn −/− and WT mice.
Periostin expression was observed to most significantly promote the accumulation of
thick collagen fibers in dermal wounds, a process characteristic of dermal scar formation.

Specific Aim II: Determine the effects of periostin expression on fibrocyte levels
following dermal injury.
Rationale: Fibrocytes contribute substantially to wound repair and fibrosis in a variety of
organs. This knowledge has motivated research studying factors that modulate fibrocyte
behavior. Based on the intersecting roles of injury-induced periostin expression and
fibrocyte infiltration, as well as previous publications investigating heart and lung
fibrosis, we hypothesized that periostin expression stimulates fibrocyte contribution to
dermal repair. Immunofluorescence microscopy and flow cytometry were used to analyze
the influence of periostin on fibrocyte activity in response to dermal injury. Periostin
gene deletion was shown to significantly reduce the number of CD45+/Col I+ fibrocytes
in the peripheral blood and in dermal wounds. This suggests a potential mechanism by
which loss of periostin delays wound closure and reduces collagen accumulation in the
reparative matrix (Aim I).

Specific Aim III: Establish the effects of periostin expression on fibrocyte trafficking.
Rationale: Chemokine-chemokine receptor interactions stimulate the mobilization,
homing, and engraftment of fibrocytes and their precursors after tissue injury. Based on
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our previous results (Aim II), we hypothesized that in addition to promoting fibroblastic
differentiation, periostin expression also promotes injury-induced fibrocyte migration. In
vitro migration and adhesion assays were performed to determine the effects of periostin
expression on CXCR4/CXCL12-induced fibrocyte chemotaxis and integrin-mediated
migration. Flow cytometry was also used to quantify in vivo differences due to loss of
periostin in the number of fibrocytes expressing the chemokine receptor CXCR4.
Periostin gene deletion was observed to significantly reduce fibrocyte adhesion and
migration in vitro and to decrease the number of circulating CXCR4+/Col I+ fibrocytes in
vivo. These findings suggest a novel role for periostin in promoting fibrocyte trafficking
in dermal wounds, specifically with regards to the CXCR4/CXCL12 signaling axis.
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CHAPTER TWO
LITERATURE REVIEW
2.1

Biology of Acute Dermal Wound Repair
Dermal wound repair is characterized by a complex series of overlapping phases,

including hemostasis and inflammation, proliferation (reepithelialization, angiogenesis,
fibroplasia, and wound contraction), and tissue remodeling (Figure 2.1)1. The key
molecular and cellular effectors that regulate each of these phases will be reviewed in the
following sections. The purpose of this review is to provide context for later sections,
which analyze studies exploring periostin upregulation and fibrocyte infiltration in
dermal wound repair.

Figure 2.1 Dermal wound repair is characterized by four overlapping phases: hemostasis,
inflammation, proliferation, and remodeling. A complex profile of cellular and molecular
effectors coordinate each phase (from Greaves et al., 2013)2.
2.1.1

Hemostasis and Inflammation
Tissue injury is characterized by the mechanical disruption of blood vessels and

the immediate extravasation of blood into the wound. To achieve rapid homeostasis,

9

vasoconstriction is induced by the release of prostaglandins and thromboxanes from
injured cells and platelets3. Platelet activation is mediated by contact with subendothelial
collagen and von Willebrand factor4. Upon activation, platelets release proinflammatory
mediators and adhesive proteins, which recruit and activate additional platelets and
induce platelet aggregation, leading to the formation of a platelet plug1. Through the
intrinsic and extrinsic coagulation pathways, the platelet plug is strengthened by the
formation of a fibrin clot, composed of largely of cross-linked fibrin, fibronectin,
vitronectin, and thrombospondin5. The fibrin clot acts as a scaffold for the attachment and
migration of leukocytes, keratinocytes, fibroblasts, and endothelial cells during
subsequent stages of wound repair. It also serves as a reservoir of platelet-secreted
growth factors that promote tissue repair6. In addition to its deposition, timely
degradation of the fibrin clot by fibrinolytic enzymes is essential for wound repair.
Inadequate removal of the provisional fibrin matrix impedes normal healing and can
cause excessive fibrosis in dermal wounds7,8.
After hemostasis is achieved, an autonomic nervous response and the secretion of
vasoactive cytokines from mast cells induces vasodilation and increases capillary
permeability3,9. This allows polymorphonuclear cells (PMNs) and monocytes to migrate
into the wound bed. PMNs clean the wound bed through phagocytosis of bacteria and
foreign particles and also secrete numerous proinflammatory cytokines5,10. Circulating
monocytes infiltrate the wound bed shortly after PMNs in response to platelet-secreted
growth factors and extracellular degradation products such as collagen and fibronectin
fragments and thrombin1,5. Monocytes are transformed into macrophages in the fibrin-
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based ECM of the wound bed. There they clear the wound bed of remaining foreign
particles, tissue debris, bacteria, and apoptotic PMNs. Macrophages maintain the
inflammatory process by secreting additional proinflammatory cytokines and also
produce numerous growth factors that stimulate reepithelialization, angiogenesis,
fibroblast migration and collagen production, and myofibroblast differentiation5,10. Large
burns and infected wounds often exhibit a prolonged inflammatory response. This results
in an increased concentration of profibrotic cytokines such as transforming growth factorβ (TGF-β) and platelet derived growth factor (PDGF), which can induce excess fibrosis
as seen in hypertrophic and keloid scars11.

2.1.2

Proliferation
The proliferative phase begins around day 3 and lasts 2-4 weeks after injury2.

Through the migration and subsequent proliferation of keratinocytes, endothelial cells,
and fibroblasts, the provisional ECM produced during hemostasis and inflammation is
reepithelialized and replaced by granulation tissue. The major events of the proliferative
phase are reepithelialization, granulation tissue formation (fibroplasia and angiogenesis),
and wound contraction.
Reepithelialization
Within 24 hours, keratinocytes from the free edges of the wound bed and
remaining hair follicles begin regenerating the epidermis by migrating across the
provisional matrix formed during hemostasis1,12. As reepithelialization progresses, a
wedge-shaped mass of keratinocytes is formed, with migrating keratinocytes at the
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leading edge, followed by a stratified layer of proliferating cells. Integrins, growth
factors, and matrix metalloproteinases (MMPs) are the main molecular effectors that
regulate the migration and proliferation of keratinocytes during wound repair. TGF-β1
and macrophage stimulating protein facilitate keratinocyte migration by activating
specific integrin receptors that allow keratinocytes to interact with ECM proteins in the
wound bed12. MMPs promote the degradation of the provisional fibrin matrix, which also
enables keratinocyte migration and the reconstruction of the basement membrane13.
Epidermal thickness is restored through rapid keratinocyte proliferation, which is
stimulated primarily by growth factors TGF-α, epidermal growth factor (EGF), and
keratinocyte growth factor5. Integrin binding as well as the processing of mitogens and
cleavage of ECM proteins by MMPs also promotes keratinocyte proliferation by
increasing the activity of growth factor receptors and their downstream mediators12.
Angiogenesis
Angiogenesis refers to the process of new vessel growth through the sprouting of
intact capillaries located adjacent to the wound bed. Newly formed blood vessels provide
nutrients and oxygen and facilitate cell migration into the granulation tissue.
Angiogenesis consists of the following steps: proteolytic degradation of the basement
membrane by MMPs, endothelial cell migration towards angiogenic stimuli to form
capillary sprouts, proliferation of endothelial cells behind leading migrating cells,
reconstruction of the basement membrane, and organization of endothelial cells into
stable capillary tubes1. Angiogenesis is regulated by signals from the serum and
surrounding ECM. Growth factors and cytokines, such as TGF-β, angiopoietin, vascular
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endothelial growth factor (VEGF), and fibroblast growth factors 1 and 2 (FGF1 and 2),
regulate angiogenesis by modulating endothelial cell proliferation, migration, integrin
receptor expression, and tubule formation14. Various ECM components, including
collagen, fibronectin, vitronectin, and laminin, provide structural support for invading
capillaries and migrating endothelial cells15.
Fibroplasia
In response to injury, fibroblasts transform from quiescent cells to migrating
proliferative biosynthetically active cells. Fibroplasia describes the migration of
fibroblasts into the wound bed and their subsequent proliferation and production of a new
collagenous ECM7. Using integrin receptors, fibroblasts migrate through the fibrin matrix
by binding and releasing provisional matrix components such as fibrin, fibronectin,
vitronectin, and hyaluronic acid. They also secrete MMPs to degrade obstacles that
impede their migration. Fibroblast migration and integrin receptor expression are
stimulated by macrophage-secreted growth factors PDGF and TGF-β5. Fibronectin has
also been shown to promote fibroblast migration into the wound bed16. Once in the
wound bed, fibroblasts gradually adopt a proliferative profibrotic phenotype and begin
producing a more permanent ECM composed largely of collagens, proteoglycans, and
elastin. Fibroblast proliferation and collagen production are also stimulated by
macrophage-secreted growth factors PDGF and TGF-β, as well as EGF and FGF-25.
Dysregulation of fibroblast function can significantly alter wound repair leading to
delayed closure or excessive fibrosis. In chronic wounds of diabetic patients, dermal
fibroblasts exhibit significantly reduced levels of proliferation17,18. In contrast, dermal
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fibroblasts isolated from keloid lesions overproduce collagen and fibronectin, leading to
excessive matrix accumulation11,19.
Wound Contraction
Wound contraction is a cell directed process that begins approximately 4 to 5 days
after injury and corresponds to the differentiation of fibroblasts into myofibroblasts15.
Myofibroblast differentiation is stimulated by the combined action of mechanical tension,
TGF-β expression, and EDA-containing fibronectin20. Myofibroblasts contain α-smooth
muscle actin (α-SMA) filaments that form an intracellular contractile apparatus. These
filaments terminate at the cell membrane to form an adhesion complex called the
fibronexus, which links intracellular actin to extracellular fibronectin21. The contraction
of α-SMA filaments generates tension across the ECM, which subsequently reduces the
size of the wound bed. Contractile forces are stabilized by myofibroblast deposition of
ECM collagen. Myofibroblasts normally undergo apoptosis after wound closure.
However, in some situations they persist and are considered to contribute to pathological
scar formation. Decreased apoptosis of myofibroblasts is thought to lead to the excessive
ECM deposition and contractures associated with hypertrophic scar formation22.
Dysregulation of myofibroblast function has also been implicated in other fibrotic
disorders, such as pulmonary fibrosis, renal fibrosis, and systemic scleroderma23,24.
Historically, myofibroblasts have been considered to originate from resident
fibroblast populations that are stimulated to develop a contractile phenotype by injuryinduced growth factors and environmental changes25. However, fibrocytes and hair
follicle progenitor cells have been proposed to represent alternative sources of
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myofibroblasts in dermal wounds26-28. Fibrocytes are circulating hematopoietic stem cell
(HSC)-derived progenitor cells that extravasate into the wound bed following injury26,29.
They have been found to contribute to wound repair by differentiating into
myofibroblast-like cells and secreting collagen type I and inflammatory cytokines30,31.
Fibrocytes have also been found to be present in high numbers in post-burn hypertrophic
scars32. The role of fibrocytes in dermal wound repair and fibrosis will be discussed in
greater detail later in this chapter.

2.1.3

Remodeling
Remodeling is characterized by a gradual change in the composition of the ECM

through balanced degradation and synthesis of ECM components over time. Specifically,
granulation tissue, which is highly vascular and rich in collagen type III, is replaced by an
ECM composed largely of collagen type I with reduced vascular density1. Fibroblasts,
neutrophils, and macrophages produce various MMPs that degrade structural ECM
proteins, specifically collagen type III15. Collagen type III degradation is accompanied by
an increase in fibroblast synthesis of collagen type I. As remodeling progresses, type I
collagen fibrils increase in diameter, undergo increased interfibril binding, and are
organized into parallel fiber bundles15,33. Cellular and vascular density is also reduced15.
In combination, these changes result in the formation of a relatively avascular and
acellular scar composed largely of parallel collagen fiber bundles.
Proteoglycans such as decorin, fibromodulin, and lumican are known to regulate
collagen fibril diameter by binding to collagen fibrils in the ECM to either inhibit or
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promote their aggregation34. There is also a growing body of evidence suggesting that
matricellular proteins play an important role in collagen fibril formation and maturation.
Rentz et al. postulated that through the surface modification of procollagen fibrils,
osteonectin mediates the association of procollagen fibrils with cells and promotes their
aggregation and integration into the ECM35. Based on in vivo evidence, Egging et al.
suggested tenascin-X (TNX) to be an important regulator of matrix maturation and
stabilization during wound healing36. Most recently, Maruhashi et al. proposed periostin
to promote collagen crosslinking by serving as a scaffold for BMP-1 mediated proteolytic
activation of lysyl oxidase (LOX)37. An increased understanding of how these
matricellular proteins modulate the deposition and maturation of ECM components
during wound repair may assist in the development of therapeutics that promote normal
wound repair in diseased tissues. The specific functions of periostin in modulating
collagen fibrillogenesis will be discussed later in this review.

2.2

Introduction to Periostin
The ECM, which continually changes in composition during wound repair, is

composed largely of collagen and elastic fibers, glycosaminoglycans, proteoglycans, and
glycoproteins. Collectively, these ECM components modulate cell migration, adhesion,
differentiation, proliferation, and apoptosis by serving as a scaffold for cells and as a
reservoir for a number of growth factors and cytokines. Historically, research efforts have
focused primarily on the role of major structural proteins in wound repair, such as
fibronectin and various types of collagen. However in recent years, this focus has
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expanded to include a small group of glycoproteins termed matricellular proteins38. A
growing body of evidence suggests that periostin, the most recently classified
matricellular protein, contributes significantly to dermal wound repair39-41. The following
sections broadly review research publications examining the expression and function of
periostin in a variety of tissue types and pathologies. The more specific functions of
periostin in dermal wound repair will be discussed after these sections.

2.2.1

Protein Structure
Periostin, originally termed osteoblast specific factor-2, was first identified as an

811-amino acid protein secreted by osteoblasts42. The protein was later renamed periostin
because of its expression in the periodontal ligament and the periosteum43. Periostin is a
90kDa glycoprotein composed of an amino-terminal EMI domain, four fasciclin-1 (Fas1)
domains with structural homology to the Drosophila Fas1 gene, and a carboxyl-terminal
domain (CTR) (Figure 2.2)43. The cysteine-rich EMI domain acts as a site for proteinprotein interactions, enabling periostin to interact directly with ECM proteins including
collagen type I and fibronectin44,45. The four Fas1 domains have been shown to bind
proteins such as tenascin-C (TNC) and bone morphogenic protein-1 (BMP-1)37,45. In
addition to binding ECM proteins, these domains have also been shown to promote
integrin-dependent cell adhesion and motility by serving as ligands for αvβ3, αvβ5, and β1
integrins46,47. The CTR domain of periostin contains a heparin binding site and
proteolytic cleavage sites that can give rise to different splice variants of periostin48.
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Through these binding domains, periostin is uniquely able to interact with both cells and
3202

the ECM environment during dermal wound repair.
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upon injury, with the wound healing responses of knockout mice typically differing from
their WT counterparts50. Examples of previously classified matricellular proteins include
thrombospondins 1 and 2, TNC, TNX, osteonectin, and osteopontin.
In 2008 Norris and colleagues proposed the classification of periostin as a
matricellular protein based on its functions in the developing and diseased murine heart51.
Periostin is highly expressed in the heart during embryonic development, where it
promotes the differentiation of mesenchymal progenitor cells into cardiac fibroblasts.
After cardiac injury, periostin promotes tissue remodeling by stimulating the integrinmediated migration of cardiac fibroblasts toward the infarct region52,53. Additional
research has further demonstrated periostin’s function as a bridge between cells and the
ECM. For example, periostin expression stimulates vascular smooth muscle cell
migration in vitro, as well as the integrin-mediated migration of epithelial ovarian cancer
cells46,54. Periostin also facilitates the maturation and assembly of collagen type I fibers in
the skin and promotes the incorporation of TNC into the ECM by calvarial
osteoblasts44,45. The expression patterns of periostin during development and after injury,
as well as the phenotype of the Pstn −/− mouse, also correspond to the characteristics of
matricellular proteins described by Bornstein. These will be discussed in the following
sections.

2.2.3

Expression in Tissues and Pathologies
The expression of periostin has been confirmed in numerous tissue types and

pathologies. Periostin plays a pivotal role in the development of the heart, where it is
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expressed by cardiac fibroblasts and aids in the organization of the ECM and in the
differentiation of the cushion mesenchyme into myofibroblastic valve tissue55-57. It has
also been found in healthy adult connective tissues, specifically in the periosteum of
bone, the periodontal ligament, and in the skin, where it is expressed by keratinocytes and
dermal fibroblasts (Figure 2.3)43,58. Periostin is prominently upregulated during ECM
remodeling after dermal injury, myocardial infarction, bone fracture, muscle injury, and
vascular injury58-62. Recent studies have also shown that periostin is highly expressed in
various human cancers, including colorectal cancer, epithelial ovarian cancer, and breast
cancer46,63,64. These studies also suggest that periostin may promote tumor growth and
metastasis. Furthermore, periostin expression has been heavily implicated in fibrotic
conditions including keloid and hypertrophic scarring, scleroderma, idiopathic pulmonary
fibrosis, subepithelial fibrosis of bronchial asthma, bone marrow fibrosis, and fibrous
dysplasia (Figure 2.3)65-70.
Healthy Skin

Hypertrophic Scar

Keloid Scar

Figure 2.3 Immunohistochemical staining of periostin in healthy skin and scar tissue.
Periostin is expressed in the basal lamina and hair follicles by keratinocytes and dermal
fibroblasts in healthy skin (black arrows). Periostin expression is associated with thick
collagen bundles in hypertrophic scar tissue (black arrows) and thinner collagen fibers in
keloid scar tissue (from Zhou et al., 2011)70.
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2.2.4

Phenotype of the Periostin Null Mouse
The development of three periostin knockout mouse models has led to numerous

discoveries regarding the role of periostin in development, disease, and wound repair71-73.
Periostin gene deletion is not lethal and Pstn −/− pups exhibit a grossly normal
phenotype. However approximately 14% of Pstn −/− mice die within 2-3 weeks of
birth71. Rios et al. hypothesized that this was due to valvular insufficiency resulting from
large acellular deposits of ECM and ectopic clusters of smooth muscle cells in the valve
leaflets71. Norris et al. observed a reduction in the diameter and crosslinking of type I
collagen fibers in the skin of adult Pstn −/− mice as well as a corresponding decrease in
skin stiffness and tensile strength44. Adult Pstn −/− mice were also found to exhibit
significant growth retardation, early onset periodontal disease, incisor enamel defects,
and incisor eruption disturbance71,72. Collectively, these phenotypic differences suggest
roles for periostin in fibroblastic differentiation and ECM maturation and organization.
Placing Pstn −/− mice on a soft diet to alleviate mechanical strain on the periodontal
ligament partially rescued their growth retardation, periodontal disease, and incisor
enamel defects71. This indicates that mechanical forces play a role in the function of
periostin.

2.3

Functions of Periostin in Dermal Wound Repair
Interest in the role of periostin during dermal wound repair has increased

considerably over the last few years. Initial publications reported changes in the
spatiotemporal expression of periostin after excisional dermal injury58,70. These findings,
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as well as the development of the Pstn −/− mouse, motivated and enabled additional
research exploring the mechanisms by which periostin facilitates dermal wound healing3941

. The findings of these studies will be discussed in the following sections.

2.3.1

Expression in Healthy and Injured Skin
The composition of the dermal ECM changes significantly between the processes

of development, tissue homeostasis, and wound healing. Understanding the specific
changes that occur provides insight regarding the biological effectors that guide each of
these processes. Periostin is highly expressed in the dermis, basement membrane, and
hair follicles during embryonic development, which suggests that it may facilitate the
initial formation of these structures70. In healthy adult skin, periostin is localized to the
basement membrane and the hair follicles70. It is also expressed by keratinocytes and
fibroblasts, but is not present in the ECM (Figure 2.4, Day 0)58. This indicates that
periostin expression in the ECM is not required for the maintenance of tissue
homeostasis.
Several studies have shown significant upregulation of periostin after dermal
injury39-41,58. Periostin can be detected in the hair follicles and in the basement membrane
1 to 3 days after injury (Figure 2.4, Day 0)39. Localization of periostin then shifts from
the cells to the granulation tissue beginning approximately 3 days after injury and
peaking at 7 days (Figure 2.4, Day 7)58. High levels of periostin expression have also
been identified in the ECM of fibrous dermal pathologies, including keloid and
hypertrophic scars as well as scleroderma lesions (Figure 2.3)69,70. The change in
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periostin localization from cells in healthy skin to the ECM during dermal remodeling
and in fibrous dermal pathologies suggests that periostin plays a significant role in the
skin’s remodeling response to injury.

Figure 2.4 Immunohistochemical staining of periostin before and after dermal injury.
White arrows indicate nuclear localization of periostin before and 3 days after injury.
Periostin expression shifts from the cells to the ECM 3 days after injury and remains
present through 21 days, peaking at 7 days (from Jackson-Boeters et al., 2009)58.
2.3.2

Proposed Mechanisms of Delayed Wound Closure in Periostin Null Mice
To date, three papers that explore the role of periostin in dermal wound repair

have been published39-41. Despite using different derivations of the Pstn −/− mouse, each
describes delayed wound closure in mice lacking periostin. In addition, one of these
papers reports accelerated closure of wounds treated with recombinant periostin41. These
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findings suggest that periostin plays an important role in wound closure and may have
therapeutic applications for the treatment of non-healing wounds. Because wound repair
is a complex process characterized by coordinated cellular activity in response to a milieu
of molecular and environmental effectors and periostin is known to modulate various cell
behaviors as well as matrix deposition in numerous tissue types, it is not surprising that
each paper investigates a different mechanism for the function of periostin in dermal
wound healing. These mechanisms include: keratinocyte proliferation, myofibroblast
differentiation, and fibroblast proliferation and migration. Table 1.1 outlines the
experimental setup and proposed mechanism of delayed closure in Pstn −/− mice for each
publication.
Nishiyama et al., 201140

Elliot et al., 201241

Ontsuka et al., 201242

Pstn −/− mouse model

Kii et al.73

Rios et al.72

Kii et al. and Rios et al.

Wound dimensions

3mm biopsy punch

6mm biopsy punch

8 or 10 mm biopsy punch

Time points of delayed
closure in Pstn −/− mice

Days 3, 5, and 8

Days 5 and 7

Days 3, 5, 7, and 11

Proposed cause of
delayed closure in Pstn
−/− mice

Delayed reepithelization
due to reduced
keratinocyte proliferation

Reduced wound
contraction due to
decreased myofibroblast
differentiation and
contraction

Impaired proliferation
and migration of dermal
fibroblasts

72,73

Table 1.1 Summary of three studies investigating the role of periostin in dermal wound
repair.
Keratinocyte Proliferation
Nishiyama and colleagues were the first to report delayed dermal wound closure
in Pstn −/− mice39. They attributed this to a defect in reepithelialization caused by
reduced keratinocyte proliferation. Hematoxylin and eosin stained sections of Pstn −/−
wounds were found to exhibit a significantly lower percent reepithelialization than WT
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wounds at 3 and 5 days after injury (Figure 2.5, A). In a later publication however, Elliot
et al. reported no significant differences in reepithelialization at day 740. This discrepancy
may be due to the analysis of wounds at different time points (3 and 5 days versus 7 days)
or to different methods of measurement. Nishiyama et al. reported their results as percent
reepithelialization, which is influenced by the size of the wound, whereas Elliot et al.
measured epithelial migration distance, which is not dependent on wound size. Elliot et
al. reported Pstn −/− wounds to be significantly larger than WT wounds at 5 and 7 days
after injury40. Therefore, the lower percent reepithelialization reported by Nishiyama et
al. may not reflect an actual delay in wound reepithelialization, but rather the increased
area of Pstn −/− wounds.
Nishiyama and colleagues also measured the proliferation of keratinocytes in the
wound beds of Pstn −/− and WT mice 3 days after injury using an antibody against the
proliferation marker Ki6739. In Pstn −/− and WT mice, a similar number of Ki67-positive
cells was found around the hair follicles of uninjured skin and in the granulation tissue
and area of migrating keratinocytes of wounded skin. However, the number of Ki67positive cells surrounding the hair follicles of injured skin was approximately twice as
high in WT mice compared to Pstn −/− mice (Figure 2.5, B). This result suggests that
early periostin expression around the hair follicles and in the basement membrane may
induce keratinocyte proliferation, leading to faster reepithelialization. The authors also
studied keratinocyte proliferation in vitro using cells from a human keratinocyte cell line
(HaCaT cells). Because they do not express significant levels of periostin, HaCaT cells
were transfected with a mouse periostin-HA construct. After one week of culture at
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confluence, overexpressing HaCaT cultures showed increased bromodeoxyuridine uptake
and higher numbers of phospho-NF-κB positive cells, suggesting that overexpression of
periostin increases human keratinocyte proliferation.
A

B

Figure 2.5 Periostin gene deletion delays reepithelialization and reduces keratinocyte
proliferation. A) H&E stained sections show delayed reepithelialization of Pstn −/−
wounds. Arrowheads and arrows represent the original wound border and the leading
edge of the reepithelialized area, respectively. The dotted line marks the area of the newly
formed epidermis. Scale bar: 50µm. B) The percentage of proliferating keratinocytes in
the bulge region of hair follicles is reduced in Pstn −/− mice after dermal injury (from
Nishiyama et al., 2011)39.
Nishiyama et al. proposed the following mechanism for periostin-induced
keratinocyte proliferation: Soon after dermal injury, periostin is expressed in the hair
follicles and basement membrane of the skin. There it acts as a scaffold protein by
binding to fibronectin, laminin 5γ2, and BMP-139. Periostin, which has been previously
shown to enhance the proteolytic activity of BMP-1, then facilitates the cleavage of
laminin 5γ2 by BMP-137. This is followed by the induction of keratinocyte proliferation
through NF-κB phosphorylation. Previous reports, which demonstrate that keratinocyte
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adhesion to laminin 5 plays a significant role in NF-κB-mediated keratinocyte
proliferation, support this proposal74,75.

Myofibroblast Differentiation
Elliot et al. also reported delayed dermal wound closure in Pstn −/− mice 5-7 days
after injury40. This delay corresponded with peak periostin expression in the granulation
tissue of WT mice. At day 7, Pstn −/− wounds were found to contain significantly fewer
myofibroblasts as evidenced by reduced α-SMA expression (Figure 2.6, A and B).
Fibroblast recruitment and collagen expression appeared to be unaltered. In vivo
application of recombinant human periostin on electrospun collagen scaffolds increased
the expression of α-SMA in the wound beds of Pstn −/− mice (Figure 2.6, C and D).
Based on these results, Elliot and colleagues proposed that the delay in would closure
was due to decreased wound contraction caused by reduced myofibroblast differentiation.
Additional support for this hypothesis was obtained through in vitro experiments. Pstn
−/− fibroblasts showed a deficit in their ability to contract a collagen matrix and reduced
α-SMA actin expression in three-dimensional and compliant two-dimensional (2D)
culture systems. Delivery of recombinant human periostin restored the ability of Pstn −/−
fibroblasts to contract collagen gels and increased their expression of α-SMA.
Additionally, the inhibition of β1 integrin binding as well as Src and focal adhesion
kinase (FAK) signaling reversed periostin-induced gel contraction by Pstn −/−
fibroblasts. From this data, the authors proposed that by binding cell surface receptors
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periostin is able to modulate intracellular signaling to facilitate myofibroblast
differentiation.
α-SMA

+/+

B

−/−

Collagen scaffold
+ periostin

A

Collagen scaffold

α-SMA
C

−/−

D

−/−

Figure 2.6 Periostin promotes α-SMA expression in the dermal wound bed. A and B)
Immunohistochemical staining reveals that Pstn −/− wounds exhibit reduced α-SMA
expression 7 days after injury relative to WT controls. C and D) Treatment of Pstn −/−
wounds with electrospun collagen scaffolds containing recombinant periostin increases αSMA expression in the wound bed (from Elliot et al., 2012)40.
Fibroblast Proliferation and Migration
Ontsuka and colleagues also examined the role of periostin in dermal wound
repair using Pstn −/− mice41. Similar to previous publications, they observed robust
periostin expression in the granulation tissue of WT mice 6-9 days after injury and
delayed wound closure in Pstn −/− mice. Ontsuka also reported that intradermal injection
of recombinant periostin restored normal wound closure kinetics in Pstn −/− mice and
accelerated the closure of WT wounds (Figure 2.7). Based on the results of several in
vitro experiments, Ontsuka and colleagues attributed the delayed closure of Pstn −/−
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wounds to impaired dermal fibroblast proliferation and migration. Using fibroblast
cultures established from the skin of newborn mice, they demonstrated that Pstn −/−
fibroblasts exhibit a decreased rate of proliferation. Treatment with recombinant periostin
slightly enhanced the proliferation of fibroblasts from Pstn −/− and WT mice, as well as
normal human dermal fibroblasts. Ontsuka et al. also performed a scratch wound assay
with mouse embryonic fibroblasts (MEFs) and showed that MEFs derived from Pstn −/−
mice had a slightly lower migratory ability compared to MEFs from WT mice.

A

B

C

Figure 2.7 Application of exogenous periostin stimulates dermal wound closure. Periostin
knockout mice (KO) exhibit delayed dermal wound closure relative to WT controls (A).
Intradermal injection of recombinant human periostin (PN) every 2 days increases the
rate of wound closure in KO (B) and WT (C) mice. *p<0.05, **p<0.01, ***p<0.001,
n=10 for each group (from Ontsuka et al., 2013)41.

29

Unfortunately the authors did not show corresponding in vivo evidence for
reduced fibroblast migration and proliferation, making it difficult to determine whether
delayed wound closure in Pstn −/− mice is caused by these deficits. In addition,
contradictory results published by Nishiyama et al. and Elliot et al. raise questions as to
the validity of their conclusions regarding in vivo wound repair39,40. In tissue sections
labeled with anti-Ki67 antibody, Nishiyama observed no difference in the number of
proliferating cells in the granulation tissue of adult Pstn −/− and WT wounds39. Elliot and
colleagues analyzed the proliferation of adult murine fibroblasts in vitro and similarly
found no difference between Pstn −/− and WT cells40. Elliot also performed a scratch
wound assay using adult dermal fibroblasts and, unlike Ontsuka, observed no difference
in the migratory ability between Pstn −/− and WT fibroblasts40. One reason for these
discrepancies may be the use of different cell sources. Ontsuka used newborn dermal
fibroblasts and MEFs while Elliot used adult dermal fibroblasts. The pattern of periostin
expression is different in developing and mature skin. Similarly, newborn and embryonic
dermal fibroblasts may respond differently than adult dermal fibroblasts to periostin. In
conclusion, while the in vitro evidence presented by Ontsuka et al. demonstrates reduced
proliferation and migration of Pstn −/− fibroblasts, the cell sources used for the in vitro
assays must be further considered and additional in vivo evidence must be obtained
before it can be concluded that periostin accelerates wound repair through fibroblast
activation.

30

2.3.3

Role in Collagen Fibrillogenesis
As discussed previously, periostin is expressed in a number of collagen-rich

connective tissues during development, growth, and wound repair. Because of this,
Norris and colleagues investigated the role of periostin in collagen fibrillogenesis and its
effect

on

the

biomechanical

properties

of

connective

tissues44.

Using

co-

immunoprecipitation assays and immunogold transmission electron microscopy (TEM),
Norris et al. demonstrated that periostin interacts directly with collagen type I. The
functional importance of this interaction was further established using Pstn −/− mice.
Skin samples from Pstn −/− mice showed reduced dermal thickness and decreased
collagen fibril diameter (Figure 2.8). Thermal denaturation temperature, which reflects
the level of collagen crosslinking in tissues, was measured using differential scanning
calorimetry. Tendons from Pstn −/− mice exhibited lower denaturation temperatures,
indicating that loss of periostin expression reduces collagen crosslinking. Furthermore,
biomechanical testing revealed that periostin gene deletion also decreases the modulus of
elasticity and ultimate tensile strength of murine skin. Collectively, this data indicates
that periostin is a regulator of collagen fibrillogenesis and an effector of the
biomechanical properties of dermal tissue.
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Figure 2.8 TEM micrographs of dermal collagen fibrils (left) and images of H&E stained
skin samples (right) show reduced fibril diameter and dermal thickness in the skin of Pstn
−/− mice. Black arrows indicate the boundaries of the dermal layer at which dermal
thickness measurements were taken (from Norris et al., 2007)44.
Norris et al. suggested that periostin may facilitate collagen type I fibril
maturation and assembly by stabilizing adjacent collagen fibrils during crosslinking or by
acting as a substrate for enzymes involved in crosslink formation44. In 2010, Maruhashi
and colleagues proposed a more specific mechanism for periostin action in collagen
crosslink formation37. Periostin was shown to promote the proteolytic activation of LOX
by BMP-1. LOX is an enzyme that is activated by BMP-1 and plays a critical role in
ECM maturation by initiating the crosslinking of collagens and elastin76. Maruhashi et al.
demonstrated that levels of active LOX protein are decreased in Pstn −/− calvarial
osteoblasts and increased in periostin-overexpressing mouse embryonic C3H10T1/2
cells. Additionally, co-immunoprecipitation assays revealed that periostin interacts
directly with BMP-1, and immunofluorescence microscopy and western blot analyses
showed that periostin promotes the deposition of BMP-1 onto fibronectin. Collectively,
these results suggest that periostin facilitates collagen crosslinking by enhancing BMP-1
deposition onto fibronectin in the ECM, which in turn promotes the proteolytic activation
of LOX.

32

2.4

Fibrocyte Participation in Wound Repair and Fibrosis
It appears that periostin contributes significantly to the dermal repair process

through its influence on cell behavior and collagen fibrillogenesis. In vivo and in vitro
experiments exploring the functions of periostin have focused on resident keratinocytes
and dermal fibroblasts, two cell types traditionally understood to direct dermal wound
repair39-41. However, recent studies indicate that cells from the bone marrow not only
contribute to the inflammatory phase, but also give rise to a population of fibroblast-like
cells, often referred to as fibrocytes, that participate in dermal wound repair and
remodeling26,29. The effect of periostin expression on fibrocyte behavior in the skin has
not been studied. However researchers have proposed a link between periostin expression
and fibrocyte contribution to fibrotic lung and heart pathologies53,73,77.
Fibrocytes were first described in 1994 by Bucala and colleagues as a distinct
population of blood-borne fibroblast-like cells that migrate into regions of tissue injury29.
They were detected in the inflammatory exudate extracted from subcutaneously
implanted wound chambers. Fibrocytes uniquely co-express mesenchymal (collagen
types I and III, vimentin, and fibronectin) and hematopoetic (CD34, CD45) cell markers,
and display an adherent, spindle-shaped morphology when cultured in vitro29. In healthy
hosts, fibrocytes are estimated to comprise 0.1% to 0.5% of the nucleated cells in the
peripheral blood26. By using chimeric mice transplanted with donor bone marrow, a
number of independent studies have established that fibrocytes and their precursors are of
bone marrow origin30,78-81. These studies also demonstrate injury-induced recruitment of
fibrocytes from the bone marrow into various organs, including the skin, heart, liver, and
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lungs. Fibrocytes have also been implicated in numerous fibrotic disorders such as
idiopathic pulmonary fibrosis, post-infarct myocardial fibrosis, and hypertrophic and
keloid scarring. The following sections will review our current understanding of fibrocyte
biology, with a focus on fibrocyte contribution to dermal wound repair and fibrotic
disorders.

2.4.1

Differentiation and Trafficking
The differentiation of fibrocytes from their hematopoietic bone marrow-derived

precursors appears to be regulated by a complex milieu of chemokines, cytokines, and
plasma proteins82. Pilling and Gomer proposed four stages during which fibrocyte
differentiation was most likely to be regulated by such factors: 1) during the production
of fibrocyte precursors in the bone marrow, 2) in the peripheral circulation, 3) as cells
traverse the endothelium, and 4) in tissues, where the final maturation and activation of
fibrocytes occurs83. They also categorized fibrocytes based on their level of
differentiation83. Early fibrocytes are lineage committed fibrocyte precursors that have
not yet elongated. Mature fibrocytes are elongated fibroblast-like cells that have migrated
into injured tissues, where they express collagen types I and III. Myofibrocytes are
derived from mature fibrocytes. They express α-SMA and appear to function similarly to
myofibroblasts in wound contraction and ECM protein production.
Fibrocytes appear to mature in culture from a subpopulation of CD14+
mononuclear cells that can be found in the bone marrow, the peripheral blood, and at
sites of tissue injury26. Several monocyte activators and profibrotic cytokines have been
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identified to influence the differentiation of CD14+ mononuclear cells into mature
fibrocytes and myofibrocytes (Figure 2.9). The profibrotic cytokines interleukin (IL)-4
and IL-13 promote the differentiation of CD14+ peripheral blood monocytes into
fibrocytes84. In contrast, the proinflammatory cytokines interferon gamma (IFN-γ) and
IL-12, as well as serum amyloid P (SAP) inhibit fibrocyte differentiation84,85.
Administration of SAP after dermal injury has been shown to reduce the number of
myofibroblasts in the wound bed and delay wound closure86. Naik-Mathuria et al.
hypothesized that these changes were due to the inhibition of fibrocyte and myofibrocyte
differentiation by SAP86. After fibrocytes differentiate from their mononuclear
precursors, further differentiation into myofibrocytes can be stimulated by TGF-β and
endothelin-1 (ET-1)26,87. Myofibrocytes produce higher levels of collagen and
fibronectin, express the myofibroblast marker α-SMA, and gradually lose their
expression of CD34 and CD4526,87,88.
CD14+
mononuclear
cell

IL-4
IL-13
TGF-β
ET-1
+++

Fibrocyte

−−−
SAP
IL-12
INF-γ

CD45, CD34

Collagen I and III
Fibronectin, α-SMA

Figure 2.9 Differentiation of CD14+ mononuclear cells into fibrocytes is regulated by a
milieu of injury-induced factors. As mononuclear precursors differentiate they lose CD45
and CD34 expression and produce higher levels of collagen types I and III, fibronectin,
and α-SMA.
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In vivo cell-tracking experiments in murine models of dermal injury and chronic
asthma have demonstrated that intravenously injected fibrocytes migrate rapidly to sites
of tissue injury26,89. Circulating cells such as monocytes, neutrophils, and T lymphocytes
migrate into injured tissues in response to chemokine signaling. This observation led
investigators to study the chemokine receptor expression profile of fibrocytes26. It was
determined that cultured human fibrocytes express CCR3, CCR5, CCR7, and CXCR4,
and that cultured murine fibrocytes express CCR7, CXCR4, and CCR226,81. Through in
vivo and in vitro studies, Abe and colleagues demonstrated that fibrocytes migrate in
response to secondary lymphoid chemokine (SLC)26. SLC is a ligand for CCR7 and has
been shown to be expressed at sites of chronic inflammation26,90. Additionally, Phillips et
al. demonstrated that circulating CXCR4+ fibrocytes migrate toward CXCL12 in vitro
and traffic to murine lungs after bleomycin-induced fibrosis88. CXCL12 is a ligand for
CXCR4 and has been shown to be upregulated in fibrotic lung tissue and dermal blister
burns88,91.
Though our understanding of the mechanisms that govern fibrocyte differentiation
and migration are not complete, current data suggests that both processes are regulated by
a complex profile of injury-induced factors. Increasing our understanding of the
molecular effectors that govern fibrocyte behavior may enable the development of novel
therapeutics that accelerate wound closure and reduce tissue fibrosis. Specifically
studying matricellular proteins like periostin, which appear to influence myofibroblast
differentiation and collagen fibrillogenesis, may further our understanding of how
fibrocytes differentiate and migrate into injured tissues.
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2.4.2

Contribution to Wound Repair
Bucala et al. first identified fibrocytes while using implanted wound chambers to

study the acute cellular response to injury29. Fibrocytes, which appeared concurrently
with circulating inflammatory cells, accounted for approximately 10% of the cells in
wound chambers and were hypothesized to contribute to scar formation based on the
increased presence of CD34+ cells in murine and human scar tissue. An abundance of
information regarding the contribution of fibrocytes to wound repair has since been
obtained from murine and human clinical investigations. Evidence suggests that
fibrocytes contribute to wound repair through multiple mechanisms, including by serving
as antigen presenting cells (APCs), promoting angiogenesis, and facilitating wound
contraction and remodeling26,29,30,92,93.
Human fibrocytes express surface proteins required for antigen presentation,
including class II major histocompatibility molecules, the co-stimulatory molecules
CD80 and CD86, and the adhesion molecules CD11a, CD54, and CD5893. Human
fibrocytes stimulate APC-dependent T cell proliferation in vitro and antigen-pulsed
murine fibrocytes migrate to proximal lymph nodes to prime naïve T cells in vivo93.
Additionally, fibrocytes secrete a number of inflammatory cytokines and are an abundant
source of potent T cell chemoattractants, including macrophage-inflammatory protein
(MIP)-1α, MIP-1β, and monocyte chemoattractant protein-1 (MCP-1)31,89,93. Collectively
this information suggests that fibrocytes promote the activation and recruitment of T cells
in inflamed tissues, thus playing an important role in initiating the immune response
during wound repair and in fibrotic disorders associated with inflammation.
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Fibrocytes also secrete several proangiogenic factors, including VEGF, b-FGF,
IL-8, and PDGF89,92. Hartlapp et al. demonstrated that endothelial cells adopt an
angiogenic phenotype characterized by increased cell migration, proliferation, and tube
formation when cultured in fibrocyte-conditioned medium containing these factors92.
Additionally, the inclusion of fibrocytes or fibrocyte-conditioned medium in matrigel
plugs was shown to increase in vivo blood vessel formation relative to fibroblast
controls92. Fibrocytes were also found to secrete high levels of MMP-9, a proteinase
found in wound exudate that mediates endothelial cell invasion during angiogenesis92.
Together, these findings demonstrate the ability of fibrocytes to promote each stage of
angiogenesis, from the dissolution of the basement membrane to the formation of
capillary tubes, through the production of proangiogenic factors.
Synthetically active fibroblasts and myofibroblasts play a critical role in wound
closure and ECM remodeling. These cells have traditionally been understood to arise
from resident dermal fibroblasts. However, a growing body of evidence suggests that
fibrocytes contribute to a unique population of bone marrow-derived fibroblast- and
myofibroblast-like cells that infiltrate dermal wounds. Abe at al. observed that fibrocytes
exhibit a TGF-β-dependent fibrotic response in vitro. Treatment of fibrocyte cultures with
TGF-β enhanced fibrocyte proliferation, myofibroblastic differentiation, and collagen
production26. Fibrocytes treated with TGF-β also exhibit increased contractile activity in
collagen gels. Mori and colleagues confirmed that fibrocytes contribute to the
myofibroblast population in vivo by showing that between 4 and 7 days after dermal
injury over 60% of fibrocytes in the wound bed also express α-SMA30. In addition to
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contributing to wound contraction and collagen production, fibrocytes also secrete
growth factors, such as connective tissue growth factor (CTGF) and TGF-β, which
promote the differentiation of resident dermal fibroblasts into myofibroblasts94.
A recently published study by Kao and colleagues demonstrates the ability of
cultured fibrocytes to enhance dermal wound healing89. After making full-thickness
excisional wounds, cultured fibrocytes were injected into the tail veins of diabetic mice.
Wound healing kinetics and the expression of soluble factors and ECM proteins were
measured. Treatment with fibrocyte injection was found to improve the rate of wound
closure through increased reepithelialization and wound contraction. Wounds of
fibrocyte-treated mice also exhibited higher blood vessel density and increased basal
keratinocyte proliferation. Real time PCR quantification of RNA expression showed that
treatment with fibrocyte injection upregulated the expression of growth factors (TGF-β,
PDGF-A, FGF-7, VEGF, and b-FGF), chemokines (MCP-1 and MIP-1α), collagen type I,
and α-SMA in dermal wounds. Collectively, these findings suggest that fibrocytes
accelerate impaired dermal wound healing by promoting reepithelialization, wound
contraction, and angiogenesis. Of note, periostin expression has also been suggested to
stimulate reepithelialization and wound contraction after dermal injury, and to promote
tumor angiogenesis39,40,95. However, the relationship between periostin expression and
fibrocyte contribution to dermal wound repair has not been examined.

2.4.3

Contribution to Tissue Fibrosis
By producing numerous injury-induced cytokines and ECM proteins, fibrocytes
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play an important role in the balance between normal wound repair and pathological
fibrosis. Despite their therapeutic usefulness in cases of impaired dermal healing,
fibrocytes, like periostin, have been implicated in numerous fibrotic conditions. The
contribution of fibrocytes to fibrotic disorders of the lungs, heart, and skin will be
discussed. Additionally, our current understanding of how periostin expression affects the
function of fibrocytes in each of these conditions will be reviewed.
Lungs
Pulmonary fibrosis, which is characterized by the accumulation of ECM proteins
within the interstitial space of the lungs, leads to the progressive destruction of lung
tissue architecture and impaired gas exchange96. Historically, activated resident
fibroblasts have been considered to be the main source of ECM proteins in pulmonary
fibrosis25. However, recent evidence from several independent studies suggests that
fibrocytes also contribute to the pathogenesis of this disease. Using a mouse model of
bleomycin-induced pulmonary fibrosis, Phillips et al. demonstrated that intravenously
injected human CD45+Col I+CXCR4+ fibrocytes and endogenous murine CD45+Col
I+CXCR4+ fibrocytes preferentially migrate to the lungs of bleomycin-challenged mice88.
The bone marrow and peripheral blood of bleomycin-challenged mice were also found to
contain a higher number of fibrocytes relative to saline-treated controls. Collagen
deposition and CXCL12 expression were significantly higher in murine lungs after
bleomycin exposure. Treatment with a neutralizing antibody against CXCL12 inhibited
fibrocyte infiltration and decreased collagen deposition in the lungs, significantly
attenuating bleomycin-induced fibrosis. Additionally, data from human studies has
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shown that patients with fibrotic interstitial lung disease have a significantly higher
number of circulating CD45+Col I+CXCR4+ fibrocytes97. Fibrocytes were also found in
the lung tissue of 8 out of 9 patients with idiopathic pulmonary fibrosis (IPF), while none
were identified in healthy human lungs98. CXCL12 was also increased in the plasma of
human patients with IPF98. Collectively, these results suggest that circulating fibrocytes
contribute significantly to pulmonary fibrosis by infiltrating the lungs in response to a
CXCL12 gradient and participating in ECM deposition.
Naik et al. recently reported that periostin expression is also increased in the lungs
of IPF patients77. Lung fibroblasts from IPF patients were shown to produce
approximately 3.5 times more periostin than lung fibroblasts from healthy controls.
Interestingly, increased periostin levels were also detected in the plasma of IPF patients,
suggesting an additional source of periostin, likely from peripheral blood cells. Naik et al.
determined that a higher percentage of circulating monocytes in IPF patients secrete
periostin and that fibrocytes cultured from the peripheral blood of IPF patients express
periostin mRNA, while fibrocytes from healthy individuals do not. Additionally, Pstn −/−
mice were protected from bleomycin-induced pulmonary fibrosis, exhibiting decreased
collagen deposition and improved lung architecture. To determine whether structural cellor hematopoetic cell-derived periostin contributes to pulmonary fibrosis, Naik et al.
generated chimeric mice through the transplantation of WT bone marrow into WT
recipients (WT à WT) or Pstn −/− recipients (WT à Pstn −/−). Complementary
chimeras were also created [(Pstn −/− à Pstn −/−) and (Pstn −/− à WT)]. Bleomycinexposure revealed that both structural and hematopoetic sources of periostin promote
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pulmonary fibrosis, as evidenced by changes in collagen deposition. Though the
relationship between periostin expression and fibrocyte behavior is not completely
understood, the data discussed above suggests a potential link between periostin
expression and fibrocyte contribution to pulmonary fibrosis.
Heart
Although connective tissue deposition and remodeling are critical to cardiac
repair, the accumulation of collagen after injury results in the formation of a nonfunctioning scar, which can lead to cardiac dysfunction73. A number of studies have
demonstrated that bone marrow-derived fibroblast-like cells, or fibrocytes, contribute to
this process of fibrotic remodeling. In a closed chest murine model of
ischemic/reperfusion cardiomyopathy (I/RC), daily 15-minute vessel occlusion episodes
were found to result in cardiac fibrosis and global left ventricular dysfunction99. Using
this model, researchers also observed a prolonged elevation of the mononuclear
chemokine MCP-1, and the infiltration of small spindle-shaped cells into the
myocardium80,99. These cells expressed markers consistent with fibrocytes, including
CD34, CD45, collagen type I, and α-SMA. The administration of SAP, which is known
to inhibit fibrocyte differentiation, largely eliminated the presence of fibrocytes in the
myocardium and also prevented I/RC induced fibrosis and ventricular dysfunction80.
Similar results were later reported in a model of angiotensin-II (Ang-II) infusion, which
induced interstitial cardiac fibrosis, hypertension, and cardiac hypertrophy in mice100.
Ang-II infusion also promoted the infiltration of spindle-shaped cells that expressed
CD34, CD45, collagen type I, and the cardiac fibroblast marker DDR2. Genetic deletion
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of MCP-1 prevented Ang-II-induced interstitial fibrosis and eliminated fibrocyte
infiltration. Together, these results suggest that interstitial cardiac fibrosis is promoted by
the induction of MCP-1 and infiltration of fibrocytes into the myocardium.
After myocardial infarction, periostin expression is highly upregulated and the
number of fibroblasts in the infarcted tissue increases substantially60,73. Oka et al.
demonstrated that global abrogation of periostin expression reduces the size of the infarct
scar73. Though periostin gene deletion increased ventricular rupture, surviving animals
were found to exhibit improved long term cardiac function. Interestingly, significantly
fewer fibroblasts were found in the infarcted myocardium of Pstn −/− mice, suggesting
that periostin modulates fibroblast behavior during cardiac remodeling. In this study,
fibroblasts were identified by immunolabeling with vimentin, a mesenchymal marker that
is also expressed by fibrocytes. Visconti et al. subjected clonal EGFP+ HSC-engrafted
mice to myocardial infarction by permanent ligation of the left anterior descending
coronary artery53. A dense population of elongated bone marrow-derived cells
surrounded by a periostin-rich ECM was observed in the infarcted tissue. These cells
exhibited a fibroblast-like morphology and, through RNA analysis, were shown to
express collagen type I, leading Visconti et al. to propose that bone marrow-derived
progenitors contribute to the formation of the post-infarct scar. Periostin was suggested to
be a potential regulator of bone marrow-derived cell fibroblastic differentiation.
However, the question of whether periostin specifically alters the contribution of
circulating fibrocytes or resident fibroblasts to myocardial scar formation remains to be
fully answered.
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Skin
Hypertrophic scar tissue has been shown to contain a greater number of fibrocytes
than mature scar tissue32. Additionally, mononuclear cells isolated from patients with
keloid scars exhibit a higher propensity to differentiate into fibrocytes in vitro and are
more resistant to the differentiation-limiting effects of SAP101. Hypertrophic and keloid
scars often form after severe thermal injury. In response to cutaneous injury, resident
fibroblasts migrate from the adjacent uninjured tissue to participate in wound repair and
remodeling. However when large areas of skin are burned long migration distances can
prevent fibroblasts from migrating to the center of the wound bed. Based on these
observations, Yang et al. hypothesized that circulating fibrocytes represent an additional
source of cells that supplement the fibroblast population and contribute to the severe
scarring often associated with thermal injury102. Yang et al. isolated mononuclear cells
from the blood of burn patients and normal individuals. Adherent cells cultured from
burn patients were observed to differentiate into fibrocytes more efficiently and to
produce higher levels of TGF-β than fibrocytes derived from healthy individuals102.
Additional studies conducted by Wang et al. suggest that fibrocytes also regulate the
activity of resident fibroblasts during cutaneous repair94. When treated with medium
conditioned by burn patient fibrocytes, dermal fibroblasts exhibited increased cell
proliferation, motility, and α-SMA expression. Wang et al. attributed these changes in
fibroblast behavior to the higher levels of profibrotic factors TGF-β1 and CTGF
produced in vitro by fibrocytes from burn patients.
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As previously discussed, periostin expression is also significantly upregulated
after dermal injury and remains elevated in hypertrophic and keloid scar tissue. However,
despite previous research in fibrotic lung and heart disorders, the relationship between
periostin expression and fibrocyte contribution to dermal repair and scar formation has
not been investigated.

2.5

Opportunities for Research
The upregulation of periostin expression and the infiltration of fibrocytes are two

distinct biological processes that have been shown to play an important role in the repair
and fibrosis of wounded and diseases tissues. As a matricellular protein, periostin
functions uniquely as a bridge between cells and the surrounding ECM during tissue
repair and remodeling. Previous research has demonstrated that periostin facilitates
(myo)fibroblastic differentiation and modulates ECM maturation and organization.
Periostin has also been shown to promote the proliferation and migration of several cell
types. Fibrocytes, derived from hematopoietic progenitor cells, differentiate and migrate
from the peripheral circulation into tissues in response to injury-induced factors. They
contribute positively to wound repair through multiple mechanisms, including by
facilitating wound contraction and remodeling, serving as APCs, and promoting
angiogenesis. Fibrocytes have also been linked to severe scar formation in organs such as
the lungs, heart, and skin. Despite their overlapping roles in tissue repair and fibrosis, the
relationship between injury-induced periostin expression and fibrocyte contribution to
wound healing remains poorly understood. This gap in knowledge represents an
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opportunity for significant advancement in our understanding of how injury-induced
matricellular proteins influence cell behavior during wound healing. Studying the specific
relationship between periostin expression and fibrocyte behavior may enable the
development of therapeutics aimed at treating non-healing wounds and preventing severe
tissue fibrosis.
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CHAPTER THREE
PERIOSTIN EXPRESSION PROMOTES COLLAGEN ACCUMULATION AND
FIBROCYTE INFILTRATION IN EXCISIONAL DERMAL WOUNDS
3.1

Introduction
Periostin is highly upregulated after injury and in fibrotic pathologies1-4. It has the

unique ability to interact with several ECM proteins, including collagen type I,
fibronectin, and TNC, as well as with multiple cell surface receptors, such as αvβ3, αvβ5,
and β15-8. Like other matricellular proteins, the functional consequences of abrogation of
periostin expression are not fully appreciated during normal tissue homeostasis but
become apparent in injured or diseased tissues. Through the use of knockout mice,
periostin has been shown to modulate collagen deposition in fibrotic heart and lung
pathologies, and to be a regulator of collagen fibrillogenesis in the skin3,5,9. Despite its
important role in scar formation, we have a limited understanding of how periostin
expression influences the reparative ECM after dermal injury. To date, three independent
studies have demonstrated that the global abrogation of periostin expression delays
dermal wound closure10-12. These studies examined the effects of periostin expression on
the behavior of local keratinocyte and fibroblast populations. Based on their observations,
altered wound repair kinetics were concluded to result from delayed reepithelialization,
decreased wound contraction, and impaired fibroblast activity.
While periostin expression has been shown to influence resident cell behavior, its
effects on circulating cells, specifically fibrocytes, have not been studied. Fibrocytes are a
distinct population of blood-borne fibroblast-like cells that migrate into regions of tissue
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injury13. They contribute to wound repair and fibrosis in several tissue types, many of
which also express periostin under pathological conditions13-20. Previously discussed
examples of pathological processes that are influenced by both periostin upregulation and
fibrocyte infiltration include: dermal wound healing, keloid and hypertrophic scarring,
pulmonary fibrosis, and interstitial myocardial fibrosis1-3,9,13,19,21. Data published by
Phillips et al., Naik et al., and Visconti et al. suggest a possible link between periostin
upregulation and fibrocyte-facilitated tissue fibrosis in the lungs and heart3,14,18. However,
the relationship between periostin upregulation and fibrocyte activity remains
incompletely understood, particularly in the area of dermal wound repair.
In this study, we used Pstn −/− and WT mice to examine how periostin expression
after dermal injury influences the composition and architecture of the reparative ECM.
Histological staining and immunolabeling techniques were used visualize gross tissue
morphology and the deposition of important ECM proteins after dermal injury. Because
we observed reduced collagen deposition in Pstn −/− wounds and previous publications
have suggested a link between periostin upregulation and fibrocyte-facilitated tissue
fibrosis, we also quantified the number of infiltrating fibrocytes in Pstn −/− and WT
wounds to determine whether differences in the reparative ECM may result from changes
in fibrocyte contribution to dermal wound healing. Pstn −/− wounds were found to
contain significantly fewer fibrocytes at late stages of wound healing, suggesting a novel
role for periostin in promoting fibrocyte contribution to dermal wound repair.
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3.2

Materials and Methods

3.2.1

Murine Model of Dermal Wound Repair
All animal studies were approved by the Institutional Animal Care and Use

Committee (IACUC) at the Medical University of South Carolina (MUSC). Pstn −/−
mice were generated using a murine model of global periostin abrogation developed by
Oka et al9. A targeting vector was used to replace exons 4 through 10 in the periostin
gene of C57BL/6 mice (Figure 3.1, A)9. Age-matched WT mice were used as controls for
all experiments. Mice were classified as Pstn −/− or WT through PCR genotyping.
A

B

Figure 3.1 Murine model of dermal wound repair. A) A targeting vector designed to
replace exons 4-10 of the periostin gene with neomycin was electroporated into mouse
embryonic stem cells, which were subsequently injected into C57/BL6 blastocysts to
generate chimeric mice. Homozygous Pstn −/− mice were bred from these chimeric
mice9. B) Full-thickness 4 mm excisional wounds were created on the dorsa of Pstn −/−
and WT mice for dermal injury studies23.
Full-thickness excisional wounds were created on the dorsa of 2-4 month Pstn −/−
and WT mice. Mice were anesthetized by 2% isofluorane nose-cone inhalation and
administered analgesia (buprenorphine, 0.1mg/kg) by intraperitoneal injection. The
dorsum of each mouse was depilated using a commercial hair removal cream (Nair,
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Church & Dwight Company Inc., Ewing, NJ) and the skin was sterilized with 10%
povidone-iodine solution and 70% ethanol. Two full-thickness excisional wounds were
made on each side of the dorsal midline at the level of the scapulae using a 4 mm biopsy
punch (Figure 3.1, B). Prior to wounding, the skin was confirmed to be in the telogen
phase of the hair cycle as evidenced by pink colored skin22. Wounds were allowed to heal
uncovered.

3.2.2

Dermal Tissue Processing for Histological Examination
Mice were euthanized by isofluorane inhalation followed by cervical dislocation

at 7, 11, and 21 days after excisional dermal injury. Tissue samples were fixed in aqueous
zinc formalin (Anatech LTD, Battle Creek, MI) overnight at 4°C and embedded in
paraffin using an automatic tissue processor (Tissue-Tek® VIP, Miles Scientific). Serial
sections (5 µm) were cut using a rotary microtome and placed on positively charged glass
slides for staining and immunofluorescence labeling.

3.2.3

Modified Movat’s Pentachrome Staining
A modified Movat’s pentachrome stain was used to study general tissue

morphology at different stages of dermal repair. This method stains nuclei and elastic
fibers black, collagen and reticular fibers yellow, ground substance and mucin blue, and
muscle and fibrin red. Tissue sections from the center of Pstn −/− and WT wounds at 7,
11, and 21 days after injury were deparaffinized in Histo-Clear II (National Diagnostics,
Atlanta, GA), rehydrated in a graded ethanol series, and mordanted in Bouin’s solution

58

for one hour. After washing thoroughly, sections were stained in 1% Alcian blue for 20
minutes, placed in alkaline alcohol for 1 hour, and stained in Verhoeff’s hematoxylin for
15 minutes. Sections were then differentiated in 2% ferric chloride, stained in Woodstain
Scarlet-Acid Fuchsin for 90 seconds, rinsed in 0.5% acetic acid water, and differentiated
in 5% phosphotungstic acid for 10 minutes. Finally, sections were rinsed in 0.5% acetic
acid followed by 100% ethanol and stained in alcoholic saffron solution for 20 minutes
before being mounted in a xylene-based mounting medium. All staining solutions were
purchased from Electron Microscopy Sciences in Hatfield, PA. Movat’s stained sections
were imaged at 4x and 40x using an Olympus BX20 microscope (Olympus America,
Center Valley, PA). At least four wounds per genotype and time point were analyzed.
The dermal and epidermal thicknesses of skin sections from Pstn −/− and WT mice
before and 7, 11, and 21 days after injury were measured using ImageJ software
(National Institutes of Health, Bethesda, MD). Measurements, which were taken at the
center of each wound bed, were analyzed using a Student’s t-test for independent samples
(IBM SPSS Statistics, IBM Corporation, Armonk, New York), where p-values <0.05
were considered significant.

3.2.4

Picro-sirius Red Staining for Collagen
Picro-sirius red staining enhances the intrinsic birefringence of collagen fibers and

can be used to analyze collagen content and fiber morphology in connective tissues.
Tissue sections from the center of Pstn −/− and WT wounds at 7, 11, and 21 days after
injury were deparaffinized in xylene and rehydrated in a graded ethanol series. Nuclei
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were stained in iron hematoxylin for 10 minutes and collagen fibers were stained in
picro-sirius red (Sigma Aldrich, St. Louis, MO) for one hour at room temperature.
Sections were rinsed in 1% glacial acetic acid, dehydrated in ethanol, and cleared in
xylene before mounting with coverslips. An Olympus BX63 microscope (Olympus
America) was used to image sections from each wound at 40x magnification under
polarized light. At least four wounds per genotype and time point were imaged. The
percent areas of thick and thin collagen fibers in each image were measured using ImageJ
software. Mean percent areas were calculated for each time point and analyzed using a
Student’s t-test for independent samples, where p-values <0.05 were considered
significant.

3.2.5

Immunofluorescence Labeling of Extracellular Matrix Proteins
Immunofluorescence microscopy was used to observe the deposition of specific

extracellular matrix proteins over the course of wound repair. Tissue sections from the
center of four Pstn −/− and four WT wounds at 7, 11, and 21 days after injury were
deparaffinized in Histo-clear II and rehydrated in a graded ethanol series. Antigen
retrieval was accomplished by placing slides in a pressure cooker containing a citric acid
based antigen-unmasking solution (Vector Laboratories, Burlington, CA) for 5 minutes.
After permeabilization in 0.1% Triton X-100 and blocking with Background Buster
(Innovex Biosciences, Richmond, CA), tissues were incubated overnight at 4°C with
primary antibodies [rabbit anti-mouse CTR-periostin and rabbit anti-mouse TNC
(provided by Dr. Stanley Hoffman at MUSC) and rabbit anti-mouse fibronectin
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(Cedarlane Laboratories, Burlington, NC)]. Primary antibodies were then localized by
incubation with Cy5-conjugated donkey anti-rabbit IgG (Jackson ImmunoResearch
Laboratories, West Grove, PA) for one hour at room temperature. Nuclear
counterstaining was achieved with Yo-Pro-1 (Molecular Probes/Life Technologies,
Eugene, OR) and sections were mounted in Fluoro-Gel (Electron Microscopy Sciences,
Hatfield, PA). A Leica SP5 laser scanning confocal microscope (Leica Microsystems
Inc., Exton, PA) was used to image sections at 10x and 63x magnification. Images were
processed for qualitative analysis using ImageJ software and Adobe Photoshop CS5
(Adobe Systems Inc., San Jose, CA).

3.2.6

Quantification of Fibrocytes
Fibrocytes can be identified by the co-expression of a hematopoietic marker

(CD45, CD34) and a mesenchymal marker (collagen type I, vimentin)24-26. To quantify
the percentage of fibrocytes in 21-day Pstn −/− and WT wounds, skin sections were
double labeled with goat anti-mouse CD45 (R&D Systems Inc., Minneapolis, MN) and
rabbit anti-mouse collagen type I (Cedarlane Laboratories) using the methods described
above. Primary antibodies were localized by incubation with Cy3-conjugated donkey
anti-goat IgG (Jackson ImmunoResearch Laboratories) and Cy5-conjugated donkey antirabbit IgG. High-powered images from at least three sections per wound and four wounds
per genotype were taken using a Leica SP5 laser scanning confocal microscope. Total
cells, CD45+ cells, and CD45+/Col I+ cells were counted using Adobe Photoshop CS5
software. Cell counts from each of the three sections per wound were summed and used
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to calculate the average percentages of CD45+ cells and CD45+/Col I+ cells in Pstn −/−
and WT wounds. Results were analyzed using a Student’s t-test for independent
variables, where p-values <0.05 were considered significant.

3.3

Results

3.3.1

Gross Tissue Morphology
Previous publications have demonstrated that periostin expression is induced after

excisional dermal wounding and is maximally upregulated 7 days after injury1,10-12. We
confirmed

these

results

in

our

murine

model

of

dermal

repair

through

immunofluorescence labeling of WT wounds with an antibody against the CTR domain
of periostin. Images taken at 10x magnification show that periostin is expressed in the
granulation tissue of WT wounds at 4, 7, and 11 days after injury, with peak expression
occurring at 7 days (Figure 3.2, A, B, and C). Additionally, images taken at 63x
magnification confirm that periostin is not expressed after dermal injury in Pstn −/− mice
(Figure 3.2, D and E).
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10x

WT, 11 days

Pstn −/−, 7 days

Figure 3.2 Immunofluorescence images of Pstn −/− and WT skin sections labeled with
anti-CTR periostin (green) and counterstained with Yo-Pro-1 nuclear stain (red). A, B,
and C) Periostin is expressed in the granulation tissue after injury, with maximal
expression occurring at 7 days. Scale bar: 500 µm. D and E) High-powered images
confirm global abrogation of periostin expression in Pstn −/− mice. Scale bar: 50 µm.
Though periostin is prominently upregulated during ECM remodeling in a variety
of tissues and has been implicated in numerous fibrotic pathologies, its influence on
dermal scarring has not been studied. To compare the effects of periostin expression on
the composition and architecture of the ECM at different stages of wound repair, Pstn −/−
and WT wounds were stained with a modified Movat’s pentachrome stain. At 4x
magnification, only slight differences in gross tissue morphology were observed between
Pstn −/− and WT mice at 7, 11, and 21 days (Figure 3.3). Most notably, Pstn −/− wounds
appeared to exhibit reduced epidermal thickness, particularly at early stages of repair
(Figure 3.3, 7 days).
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WT

Pstn −/−

Days after injury

7

11

21

Figure 3.3 Images of Pstn −/− and WT dermal wounds stained with modified Movat’s
pentachrome. Scale bar: 0.5 mm.
To quantify this difference and to determine whether a loss of periostin also
decreases dermal thickness, we measured the epidermal and dermal thicknesses of Pstn
−/− and WT wounds using Movat’s pentachrome stained sections (Figure 3.4, A and B).
Dermal thickness measurements were not statistically different between Pstn −/− and WT
mice before or at any time point after skin injury (Figure 3.4, B). However at 7 and 21
days, epidermal thickness values were significantly lower in Pstn −/− mice relative to
WT mice (Figure 3.4, A). Average epidermal thickness values were approximately 110
µm and 23 µm in Pstn −/− mice and 189 µm and 49 µm in WT mice at 7 and 21 days,
respectively (p= 0.022 and p= 0.021). These results substantiate previous findings by
Nishiyama et al., which demonstrate that Pstn −/− mice exhibit delayed wound
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reepithelialization and suggest reduced keratinocyte proliferation in the absence of
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Figure 3.4 Measurements of epidermal and dermal thickness in Pstn −/− and WT wounds
before and after dermal injury. A) Epidermal thickness is reduced in Pstn −/− mice at 7
and 21 days. B) Dermal thickness is not altered by periostin gene deletion during
cutaneous wound repair. *p<0.05
3.3.2

Composition and Organization of the Reparative Extracellular Matrix
To further study whether periostin expression influences the composition and

architecture of the reparative ECM, Movat’s stained sections were also imaged at 40x
magnification. No consistent differences were observed in the reparative ECM of Pstn
−/− and WT wounds at 7 or 11 days after injury (Figure 3.5, 7 and 11 days). However at
21 days, collagen content and fiber thickness appeared to be reduced in Pstn −/− wounds
compared to WT wounds (Figure 3.5, 21 days).
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Days after injury
11

21

Pstn −/−

WT

7

Figure 3.5 Images of Pstn −/− and WT dermal wounds stained with modified Movat’s
pentachrome. At 40x magnification, 21-day WT wounds appear to contain higher
collagen content and thicker collagen fibers than 21-day Pstn −/− wounds. Scale bar: 100
µm.
Periostin gene deletion has been shown to reduce collagen fibril diameter and
decrease collagen crosslinking in healthy connective tissues5. To quantitatively assess
whether periostin expression influences collagen content and fiber morphology after
dermal injury, skin sections from Pstn −/− and WT wounds were stained with picro-sirius
red and imaged under polarized light. Under polarized light, thicker collagen fibers
appear red/orange and thinner collagen fibers appear green/yellow. Some researchers
have suggested that fiber color can be used to determine collagen type, with red/orange
fibers representing collagen type I and green/yellow fibers representing collagen type
III27. However, though collagen type I fibers are generally thicker than type III fibers,
immature collagen type I fibers may also appear green/yellow, especially during early
wound remodeling28. Thus when analyzing picro-sirius red stained sections, we will
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describe collagen fibers as thick or thin, with the understanding that collagen type I fibers
are typically, but not always represented by thick or red/orange fibers.
Similar to Movat’s stained sections, collagen content and fiber diameter appeared
to be reduced in 21-day Pstn −/− wounds stained with picro-sirius red. Representative
images of 21-day picro-sirius red stained sections are shown in Figure 3.6, A and B.
Collagen content was quantified using ImageJ software to measure the percent area of
each fiber type in images taken at 40x magnification. In the absence of periostin, thick
collagen fiber content was significantly reduced at 21 days after injury, with the average
percent area of thick collagen fibers in Pstn −/− wounds equaling 9.4% versus 15.8% in
WT wounds (p=0.045, Figure 3.6, C). Differences between Pstn −/− and WT wounds in
thick fiber content at earlier time points and in thin fiber content throughout dermal repair
were not significant (Figure 3.6, D). Collectively, these results suggest that periostin
expression increases the accumulation of thick fibers, which likely represent collagen
type I fibers, in later stages of dermal repair.
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Figure 3.6 Analysis of dermal collagen content by picro-sirius red staining. A and B)
Images of picro-sirius red stained sections taken at 40x magnification under polarized
light suggest that collagen fiber content is reduced in Pstn −/− wounds at 21 days after
dermal injury. Scale bar: 100 µm. C and D) Quantitative measurements of thick and thin
fiber content indicate that thick fiber content is significantly reduced in Pstn −/− wounds
at 21 days after injury. *p<0.05
In addition to interacting directly with collagen type I, periostin also binds to TNC
and fibronectin6. In calvarial osteoblast cultures, periostin has been shown to play a
critical role in incorporating these proteins into the architecture of the ECM6. To our
knowledge however, the influence of periostin expression on TNC and fibronectin
deposition in dermal wounds has not been investigated. To study this, tissue sections
from Pstn −/− and WT mice at 7, 11, and 21 days after injury were labeled with
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antibodies against TNC and fibronectin. In general, Pstn −/− wounds were observed to
express slightly lower levels of TNC than WT wounds at 7 and 11 days after injury, as
indicated by reduced fluorescent signals (Figure 3.7). TNC deposition also appeared to be
more granular and less associated with ECM fibers in a majority of Pstn −/− wounds at
these time points. At 7 days, fibronectin expression was observed to be higher in 3 out of
5 WT wounds relative to Pstn −/− wounds. No differences were observed in the
morphology of fibronectin fibrils between Pstn −/− and WT mice. Representative images
of 7-day Pstn −/− and WT wounds labeled with fibronectin are shown in Figure 3.8.
WT

Pstn −/−

Days after injury

7

11

Figure 3.7 Immunofluorescence images of Pstn −/− and WT wounds labeled with antiTNC (green) and counterstained with Yo-Pro-1 nuclear stain (red). Minimal TNC
expression was observed at 21 days (data not shown). TNC expression appeared to be
slightly reduced and more granular at 7 and 11 days after injury in Pstn −/− wounds
compared to WT wounds. Scale bar: 50 µm.
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Pstn −/−

63x

10x

WT

Figure 3.8 Immunofluorescence images of Pstn −/− and WT wounds labeled with antifibronectin (green) and counterstained with Yo-Pro-1 nuclear stain (red). Minimal
fibronectin expression was observed at 11 and 21 days (data not shown). Higher levels of
fibronectin expression were observed in a majority of WT wounds compared to Pstn −/−
wounds. Scale bar at 10x: 500 µm, at 63x: 50 µm.
3.3.3

Fibrocyte Infiltration into the Wound Bed
Periostin has been described as a profibrogenic protein that mediates both ECM

protein synthesis and fibroblast differentiation1,29. Our results suggest that periostin
expression increases collagen content in dermal scar tissue. The purpose of this
experiment was to determine whether bone marrow-derived cells represent a source of
this increase. Fibrocytes are commonly identified by the co-expression of CD45 and
collagen26. To establish the effects of periostin expression on fibrocyte infiltration into
the wound bed, tissue sections from the center of 21-day Pstn −/− and WT wounds were
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labeled with antibodies against CD45 and collagen type I. Sections were imaged at 63x
magnification and the number of total cells, CD45+ cells, and CD45+/Col I+ cells were
counted for each wound. Representative images of labeled tissue sections are shown in
Figure 3.9, A. The average percentage of CD45+/Col I+ cells was calculated to be over
four times higher in WT wounds than in Pstn −/− wounds (2.52% in Pstn −/− and 10.16%
in WT, p= 0.00013, Figure 3.9, B). This indicates that periostin expression increases the
number of fibrocytes present in dermal wounds. The average percentage of CD45+ cells
in WT wounds was slightly lower than in Pstn −/− wounds. However, this difference was
not statistically significant (17.93% in Pstn −/− and 23.80% in WT, p= 0.566, Figure 3.9,
B).
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Figure 3.9 Quantification of fibrocytes in 21-day dermal wounds. A) Pstn −/− and WT
wounds were immunolabeled with anti-CD45 (red), anti-collagen type I (green), and YoPro-1 nuclear stain (blue). White arrows indicate CD45+/Col I+ cells. Scale bar: 50 µm.
B) The percentages of CD45+ cells and CD45+/Col I+ cells were calculated. At 21 days,
WT wounds were found to have a significantly higher number of CD45+/Col I+ cells
relative to Pstn −/− wounds. ***p<0.001
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3.4

Discussion
Impaired dermal wound healing can manifest either as delayed wound closure

(non-healing chronic wounds) or as excessive wound fibrosis (keloid or hypertrophic
scars). Previous studies have focused on the function of periostin in dermal wound
closure, demonstrating its potential applications for the treatment of non-healing dermal
lesions10-12. However, periostin expression has also been implicated in dermal
fibroproliferative disorders, which due to an overabundant deposition of collagen fibers
result in excessive scarring2. In this study, we showed that periostin gene deletion alters
scar tissue composition by reducing collagen content during later phases of wound
remodeling. We also investigated bone marrow-derived cells as potential contributors to
this change and demonstrated that the global abrogation of periostin reduces fibrocyte
contribution to dermal wound healing.
Periostin can interact directly with several ECM proteins that are secreted during
dermal wound repair, including collagen type I, TNC, and fibronectin5,6. We studied the
expression of these proteins in Pstn −/− and WT mice after excisional dermal wounding
to determine whether periostin influences their expression in the reparative matrix.
Analysis of Movat’s pentachrome and picro-sirius red stained sections revealed that thick
collagen fiber content is significantly reduced in the scar tissue of 21-day Pstn −/−
wounds. Recent studies have shown that loss of periostin expression reduces collagen
accumulation and improves tissue architecture in murine hearts after myocardial
infarction and in murine lungs after bleomycin-induced pulmonary fibrosis3,9. Periostin
gene deletion has also been observed to reduce collagen fibril diameter and crosslinking
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in murine skin and tendons, suggesting that periostin plays an important role in collagen
fibrillogenesis5. Collectively, these observations correspond with our results, which
demonstrate that loss of periostin expression reduces the accumulation of thick collagen
fibers in dermal scar tissue.
Periostin gene deletion has also been shown to alter the meshwork architecture of
the ECM in the periosteum and in calvarial osteoblast cultures, specifically with respect
to TNC and fibronectin deposition6. To determine whether similar changes occur in the
reparative dermal ECM, we used immunofluorescence microscopy to localize TNC and
fibronectin expression at different stages of dermal repair. Previously, Kii et al. reported
that loss of periostin expression significantly reduces TNC deposition in the periosteum6.
In this study, Pstn −/− mice were also observed to express lower levels of TNC than WT
mice after dermal injury. However, the reduction in fluorescent signal was not as
significant as previously reported in the periosteum. TNC deposition also appeared to be
more granular and less associated with the dermal ECM in Pstn −/− mice, a difference
also detected in Pstn −/− calvarial osteoblast cultures6. Periostin has been proposed to
function as a bridge between TNC and the ECM through its EMI and fasciclin-1
domains, which interact with collagen type I and fibronectin, respectively6,30. Reduced
deposition of TNC on the reparative dermal ECM in Pstn −/− mice is likely a result of
this function of periostin. Interestingly, periostin is expressed under homeostatic
conditions in the periosteum, but not in the dermis1,31. Homeostatic expression of
periostin may cause periostin gene deletion to affect the ECM architecture of the
periosteum to a greater degree than that of injured skin.
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Kii et al. also observed the fibronectin network produced by Pstn −/− calvarial
osteoblasts to contain thicker fibers with fewer branched connections relative to the fine
fibronectin meshwork produced by WT cells6. In contrast, we did not observe differences
in fibronectin fibril morphology after dermal injury. As with TNC, fibronectin expression
did however appear to be slightly reduced in Pstn −/− wounds. Decreased fibronectin
expression after dermal injury has previously been observed in TNC −/− mice32. This
suggests that reduced TNC expression due to periostin gene deletion may also decrease
fibronectin expression in dermal wounds. Collectively, our results indicate that a loss of
periostin slightly alters the deposition of both TNC and fibronectin in the reparative
ECM. However, these changes are less dramatic than those observed in the periosteum
and in osteoblast cell cultures. Overall, global abrogation of periostin appears to most
significantly alter collagen accumulation in the reparative dermal ECM.
Research investigating the role of periostin in dermal wound healing has focused
largely on the activity of local keratinocyte and fibroblast populations10-12. However, an
increasing body of evidence suggests that bone marrow-derived fibrocytes play an
important role in dermal wound repair and fibrosis13,20,21,33-36. To determine whether
reduced collagen accumulation at 21 days may result from changes in fibrocyte
contribution to dermal wound repair, 21-day Pstn −/− and WT wounds were labeled with
antibodies against CD45 and collagen type I. The total percentage of bone marrowderived cells murine wounds was not significantly altered by periostin gene deletion. This
indicates that periostin expression does not substantially influence the inflammatory
response at 21 days after dermal injury. Interestingly however, periostin gene deletion
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was found to significantly reduce the number of fibrocytes in 21-day dermal wounds.
Fibrocytes have been shown to participate in tissue remodeling through ECM protein
production and to promote fibroblast proliferation, migration, and collagen production
through the secretion of several soluble factors. Therefore, the elevated number of
fibrocytes observed in 21-day WT wounds may contribute to the increase in collagen
accumulation either directly through the production of ECM components or indirectly by
influencing fibroblast behavior through the production of profibrotic factors.
Periostin has previously been shown to promote the fibroblastic differentiation of
mesenchymal progenitor cells in the heart, as well as the myofibroblastic differentiation
of dermal fibroblasts after injury11,29. Several research groups have also demonstrated that
periostin enhances the motility of different cell types including murine embryonic
fibroblasts, ovarian epithelial cells, cardiac fibroblasts, and vascular smooth muscle
cells7,8,12,37. In light of these reports, our results suggest that periostin expression after
dermal injury may influence fibrocyte behavior by promoting the fibroblastic
differentiation of fibrocytes from their bone marrow-derived precursors and/or by
stimulating the migration of fibrocytes and their precursors into dermal wounds. Both
mechanisms would result in the increased fibrocytes levels that we observed in WT mice
21 days after dermal injury.

3.5

Conclusions
In this study, we demonstrate that periostin is a profibrogenic matricellular protein

that enhances collagen accumulation in the reparative ECM after dermal injury. We also
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establish that periostin expression increases the contribution of fibrocytes to dermal
wound repair. Fibrocytes represent an additional source of collagen and profibrotic
factors in the reparative ECM and, in response to periostin expression, appear to
contribute significantly to dermal remodeling. Although the involvement of periostin in
tissue fibrosis has been well demonstrated in various diseases, the physiological functions
of periostin in dermal scar formation are just beginning to be explored. The results
presented in this chapter demonstrate a novel role for periostin in promoting fibrocyte
contribution to late phases of dermal wound repair.

3.6
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CHAPTER FOUR
PERIOSTIN EXPRESSION ELEVATES FIBROCYTE LEVELS IN THE
PERIPHERAL BLOOD AND SKIN AFTER DERMAL INJURY
4.1.

Introduction
Fibrocytes were first described in 1994 by Bucala and colleagues when they

identified a unique population of blood-borne fibroblast-like cells in subcutaneously
implanted wound chambers1. Through the use of chimeric mouse models, several
independent studies have since demonstrated that fibrocytes originate from the bone
marrow and migrate into various tissues in response to injury2-6. Though our
understanding of the mechanisms that govern fibrocyte differentiation and trafficking are
not complete, current data suggests that these processes are regulated by a complex
profile of chemokines, cytokines, and plasma proteins produced in response to injury7-10.
Fibrocyte infiltration into tissues affected by acute injury or fibrosis has been well
established in numerous organs1,5,10-13. Moreover, increased fibrocyte levels have also
been observed in the bone marrow of mice with bleomycin-induced pulmonary fibrosis
and in the peripheral blood of patients with fibrotic conditions such as hypertensive heart
disease, pulmonary fibrosis, and systemic sclerosis10,14-17. Collectively, these reports
suggest that regulation of fibrocyte behavior by injury-induced factors is likely to occur
at multiple stages, affecting fibrocytes and their precursors in the bone marrow, in the
peripheral circulation, and at sites of tissue injury.
As previously described in Chapter 3, we observed fewer fibrocytes in the wound
beds of Pstn −/− mice and a corresponding decrease in thick collagen fiber content at late
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phases of wound repair. Although these findings suggest a novel role for periostin in
promoting fibrocyte contribution to dermal remodeling, the impact of periostin
expression on fibrocyte levels during early wound healing and outside of the wound bed
has not previously been studied. In this chapter, we measured the number of CD45+/Col
I+ fibrocytes present at early phases of repair in the skin, bone marrow, and peripheral
blood of WT mice. Dermal injury was shown to increase fibrocyte levels in murine
wound beds and in the peripheral blood. Pstn −/− mice were then used to determine
whether periostin expression contributes to this increase. Periostin gene deletion was
observed to significantly reduce fibrocyte levels present in the skin and peripheral blood
after dermal injury. Similar to our previous findings, the work presented in this chapter
demonstrates that periostin expression stimulates fibrocyte contribution to early phases of
dermal repair. Our results also suggest that periostin expression influences bone marrowderived cell behavior outside of the dermal wound bed.

4.2.

Materials and Methods

4.2.1. Murine Model of Dermal Wound Repair
All animal studies were approved by IACUC at MUSC. As discussed previously,
Pstn −/− mice were generated using a murine model of global periostin abrogation
developed by Oka et al18. Age-matched WT C57BL/6 mice were used as controls for all
experiments. Mice were classified as Pstn −/− or WT through PCR genotyping. Fullthickness excisional wounds were created on the dorsa of 2-4 month Pstn −/− and WT
mice using methods described previously in Section 3.2.1. Briefly, two 4 mm excisional
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dermal wounds were made on either side of the dorsal midline following anesthetization
and administration of appropriate analgesia. A depilatory cream was applied prior to
wounding and the skin was confirmed to be in the telogen phase of the hair cycle as
evidenced by pink colored skin19. Wounds were allowed to heal uncovered.

4.2.2. Isolation of Dermal Wound Bed Cells
Uniformly sized skin samples from 4 and 7-day Pstn −/− and WT wound beds
were obtained using a 4 mm biopsy punch. Three mice per time point and genotype were
used for this experiment and mice were euthanized by isofluorane inhalation followed by
cervical dislocation prior harvesting skin samples. As described by Wilson et al., the skin
samples were cut into 1 mm2 pieces and incubated overnight at 4°C in Solution A [1 ml
HBSS containing 1 mg/ml Dispase I (Sigma Aldrich), 3% FBS, and 1x antibioticantimycotic solution]20. The remaining tissue was then removed from Solution A, further
minced, and incubated while shaking at 37°C in Solution B [4 ml of high glucose DMEM
containing 1 mg/ml hyaluronidase I (Sigma Aldrich), 1 mg/ml collagenase D (Roche
Diagnostics, Mannheim, Germany) and 150 U/ml DNAse]. After approximately 1 hour,
the cell suspension was agitated with a 1 ml pipette and combined with Solution A,
passed through a 70 µm cell strainer, and washed twice in complete media [high glucose
DMEM (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal
bovine serum (FBS, Atlanta Biologicals, Atlanta, GA), 10% mouse serum (Atlanta
Biologicals), 1x GlutaMAX (Gibco/Life Technologies), 1% penicillin streptomycin
(Gibco/Life Technologies), and 1x antibiotic-antimycotic solution (Sigma Aldrich)].
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Cells were allowed to recover in complete media at 37°C for 45 minutes. Cells were then
centrifuged at 1500 rpm for 5 minutes and resuspended in ice-cold fluorescence activated
cell sorting (FACS) buffer [1% BSA (Sigma Aldrich) in PBS with DNAse (Thermo
Fisher Scientific Inc., Waltham, MA)] for antibody labeling.

4.2.3. Isolation of Bone Marrow Cells
Bone marrow cells were isolated from a minimum of three Pstn −/− and three WT
mice before and 4, 7, and 11 days after dermal injury. Mice were euthanized by
isofluorane inhalation followed by cervical dislocation. Using a 1 cc insulin syringe, bone
marrow cells were flushed from the femurs and tibiae of mice with complete media. The
cells in complete media were aspirated through a 22-gauge needle and triturated several
times to generate a single cell suspension. The homogenized cell suspension was then
filtered through a 70 µm cell strainer, centrifuged at 1500 rpm for 5 minutes, and
resuspended in ice-cold FACS buffer for antibody labeling.

4.2.4. Isolation of Peripheral Blood Cells
Blood samples (~50 µl) were obtained by retro-orbital bleeding of Pstn −/− and
WT mice before and 4, 7, and 11 days after dermal wounding. Red blood cells were lysed
with lysis buffer (BD Pharm Lyse, BD Biosciences, San Jose, CA) and the remaining
peripheral blood cell suspension was centrifuged at 1500 rpm for 5 minutes. After
dumping the supernatant, cells were resuspended in ice-cold FACS buffer for antibody
labeling. Peripheral blood was obtained from a minimum of four mice per genotype at
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each time point. Mice were maintained under isofluorane-induced anesthesia throughout
the procedure.

4.2.5. Flow Cytometry Analysis
Cells isolated from the skin, bone marrow, and peripheral blood of Pstn −/− and
WT mice were analyzed by flow cytometry using previously published methods with
modifications10,12. Cells were incubated in allophycocyanin-Cy7-conjugated (APC-Cy7)
CD45 (BD Biosciences) in FACS buffer at 4°C for 40 minutes. Subsequently, cells were
fixed and permeabilized using a cytofix/cytoperm kit (BD Biosciences) to enable
intracellular staining of collagen type I. Cells were then labeled for 30 minutes at 4°C
with rabbit anti-collagen type I (Rockland Immunochemicals Inc., Gilbertsville, PA)
followed by fluorescein isothiocyanate-conjugated (FITC) donkey anti-rabbit IgG
(Jackson ImmunoResearch). Cells were washed twice in FACS buffer and analyzed on a
MoFlo Atrios cell sorter using Summit v6.1 software (Beckman Coulter, Indianapolis,
IN). A minimum of 10,000 cells was analyzed per condition. The average percentage of
CD45+/Col I+ fibrocytes was calculated for each time point and genotype. Data was
analyzed using a Student’s t-test for independent samples, where p-values <0.05 were
considered significant.
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4.3.

Results

4.3.1. Fibrocyte Population in the Skin
Our previous results show that at late stages of dermal repair, WT wounds contain
a significantly higher number of fibrocytes compared to Pstn −/− wounds. To determine
whether periostin expression also increases the number of fibrocytes in the wound bed at
early stages of dermal repair, we used flow cytometry to measure the percentage of
fibrocytes in Pstn −/− and WT wounds at 4 and 7 days after injury. At these time points,
we observed distinct CD45+/Col I+ and CD45−/Col I+ cell populations in the wound beds
of both Pstn −/− and WT mice. These populations, which denote fibrocytes and resident
fibroblasts, respectively, can be clearly seen in the representative 2D plots shown in
Figure 4.1.
We used these plots to calculate the average percentage of fibrocytes and resident
fibroblasts in Pstn −/− and WT wounds at each time point. The percentage of fibrocytes
in both Pstn −/− and WT wounds was found to increase significantly between days 4 and
7, from 4.22% to 14.69% in Pstn −/− wounds (p=0.044) and 4.28% to 24.38% in WT
wounds (p=0.00016, Figure 4.2, A). These results support previously published data,
which shows the percentage of fibrocytes in human dermal wounds to increase
substantially between 4 and 14 days after injury21. The percentage of resident fibroblasts
also increased significantly between 4 and 7 days in both groups, from 4.83% to 22.85%
in Pstn −/− wounds (p=0.004) and 4.10% to 20.90% in WT wounds (p=0.003, Figure 4.2,
B).
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Pstn −/−

WT

CD45-/Coll+

CD45-/Coll+
CD45+/Coll+

CD45+/Coll+

CD45-/Coll+

CD45-/Coll+
CD45+/Coll+

CD45+/Coll+

Figure 4.1 Fibrocyte and fibroblast subsets in Pstn −/− and WT wounds. Primary data
demonstrates that fluorescence levels in unstained controls (top) are readily distinguished
from fluorescence levels provided by cells labeled with anti-CD45 and anti-collagen I
antibodies (bottom). Distinct populations of CD45+/Col I+ and CD45−/Col I+ cells, which
represent fibrocytes and fibroblasts, can also be observed in 7-day wounds.
Interestingly, while no differences in fibrocyte number were observed between
Pstn −/− and WT mice at 4 days after injury, loss of periostin expression was found to
significantly reduce the percentage of fibrocytes present in 7-day dermal wounds. At 7
days, fibrocytes comprised 24.38% of cells in WT wounds and only 14.69% of cells in
Pstn −/− wounds (p=0.025, Figure 4.2, A). Periostin gene deletion did not alter the
percentage of resident fibroblasts at either time point (Figure 4.2, B). To determine
whether a loss of periostin reduces total bone marrow-derived cell infiltration into the

86

wound bed, we also calculated the average percentage of CD45+ cells in Pstn −/− and WT
wounds. The average percentage of CD45+ cells at 7 days was lower in Pstn −/− mice
than in WT mice (34.81% versus 48.90%, p=0.127). However, this difference was not
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statistically significant (Figure 4.3).
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Figure 4.2 Quantification of fibrocyte and fibroblast levels in Pstn −/− and WT wounds.
A) The average percentage of CD45+/Col I+ cells was significantly higher in WT wounds
than in Pstn −/− wounds at 7 days after dermal injury. B) Loss of periostin did not alter
the average percentage of CD45−/Col I+ cells at 4 or 7-day wounds. *p<0.05
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Figure 4.3 Quantification of bone marrow-derived cells in Pstn −/− and WT wounds. A
and B) Gates were set based on fluorescence levels in unlabeled control samples.
Representative histograms of unlabeled cells (A) and cells labeled with an antibody
against CD45 (B) are shown. C) Loss of periostin did not significantly reduce the number
of CD45+ cells in Pstn −/− wounds at 4 or 7 days.
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Collectively, these results demonstrate that a loss of periostin reduces the number
of fibrocytes in injured dermal tissue, but does not alter the number of resident fibroblasts
in the wound bed at early stages of repair. While differences in the percentage of CD45+
cells were not significant, reduced migration of bone marrow-derived cells into Pstn −/−
wounds may contribute to the observable decrease in fibrocyte number. In the next
experimental sections we examined the effects of periostin gene deletion on fibrocyte
levels in the bone marrow and peripheral blood to determine whether periostin expression
influences fibrocyte behavior outside of the injured tissue.

4.3.2. Fibrocyte Population in the Bone Marrow
Bleomycin-induced pulmonary fibrosis has been shown to dramatically increase
the number of fibrocytes in murine bone marrow10. Based on this finding, investigators
have proposed the bone marrow to be a significant source of circulating fibrocytes that
migrate into injured lung tissue10. To our knowledge, the effects of dermal injury, as well
as periostin expression, on fibrocyte levels in the bone marrow have not been studied. To
examine these effects, bone marrow was recovered from Pstn −/− and WT mice before
and 4, 7, and 11 days after dermal injury, labeled with antibodies against CD45 and
collagen type I, and analyzed by flow cytometry. We identified a small population of
CD45+/Col I+ cells in the bone marrow of Pstn −/− and WT mice (Figure 4.4). The
average percentage of this population did not change significantly before or at any time
point after dermal injury (Figure 4.5). This indicates that our model of excisional dermal
wounding does not stimulate the same profibrotic response in the bone marrow as
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bleomycin-induced pulmonary fibrosis. Additionally, no differences in the number of
fibrocytes present in the bone marrow were observed between Pstn −/− and WT mice
(Figure 4.5). These results suggest that periostin expression does not influence fibrocyte
differentiation in the bone marrow after dermal injury. However because our injury
model did not stimulate an increase in bone marrow fibrocyte number, using an injury
model that does may provide a better perspective on how periostin expression influences
fibrocyte formation in the bone marrow.
WT

Pstn −/−

Figure 4.4 Fibrocyte subsets in bone marrow harvested from uninjured Pstn −/− and WT
mice (R16). Primary data demonstrates that fluorescence levels in unstained controls
(top) are readily distinguished from fluorescence levels provided by cells labeled with
anti-CD45 and anti-collagen I antibodies (bottom).
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Figure 4.5 Quantification of fibrocyte levels in the bone marrow of Pstn −/− and WT
mice before and after dermal injury. Dermal injury did not induce a significant increase
in the number of CD45+/Col I+ cells. No differences in fibrocyte levels were observed
between Pstn −/− and WT mice.
4.3.3. Fibrocyte Population in the Blood
In healthy hosts, fibrocytes are estimated to comprise 0.1% to 0.5% of the
nucleated cells in the peripheral blood1. However, this percentage has been shown to be
elevated in patients with several fibrotic disorders, suggesting that injury-induced factors
also affect fibrocytes and their precursors in the peripheral circulation. To determine
whether dermal injury also causes the number of circulating fibrocytes to increase,
peripheral blood was sampled from WT mice before and after dermal injury and labeled
with antibodies against CD45 and collagen type I for flow cytometry analysis.
Representative 2D plots of labeled peripheral blood cells before and 4 days after injury
are shown in Figure 4.6. CD45+/Col I+ cells are located in region R20.
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Pstn −/−

4 days

0 days

WT

Figure 4.6 Fibrocyte subsets in the peripheral blood of Pstn −/− and WT mice before and
4 days after injury (R20). Representative histograms show a visible increase in the
percentage of CD45+/Col I+ fibrocytes after dermal wounding in Pstn −/− and WT mice.
These 2D plots were used to calculate the average percentage of CD45+/Col I+
cells in the peripheral blood at each time point. Dermal injury was found to induce a
significant increase in the number of circulating fibrocytes in WT mice (Figure 4.7). The
percentage of fibrocytes in the peripheral blood was highest at 4 days, increasing from
0.62% before injury to 4.2% 4 days after injury (p=2.62x10-5). After 4 days, the number
of circulating fibrocytes gradually decreased before returning to uninjured levels at 11
days. As with previous studies, we also used Pstn −/− mice to determine if these changes
were related to injury-induced periostin expression. The average percentage of circulating
fibrocytes in Pstn −/− mice at 4 days after injury was also significantly higher than in
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uninjured controls (0.42% to 2.07%, p=0.013). Prior to dermal injury, Pstn −/− and WT
mice were found to contain a similar percentage of peripheral blood fibrocytes. In WT
mice however, dermal injury induced a significantly higher increase in the number of
circulating fibrocytes. At 4 days, fibrocytes comprised 4.20% of cells in WT blood and
only 2.07% of cells in Pstn −/− blood (p=0.008). Additionally, though the overall
percentage of fibrocytes was decreased in both genotypes at 7 days, the percentage of
circulating fibrocytes in WT mice remained statistically higher, comprising 1.47% of
cells in WT blood and only 0.34% of cells in Pstn −/− blood (p=0.0003). These results
indicate that periostin expression induced by dermal injury significantly enhances

Percent CD45+/Col I+ cells in the blood

fibrocytes levels in the peripheral blood at early stages of wound repair.
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Figure 4.7 Quantification of fibrocyte levels in the peripheral blood of Pstn −/− and WT
mice before and after dermal injury. Dermal injury induced a significant increase the
percentage of circulating fibrocytes in both Pstn −/− and WT mice, with fibrocyte levels
peaking at 4 days after injury. WT mice also exhibited a significantly higher percentage
of circulating fibrocytes compared to Pstn −/− mice at 4, 7, and 11 days after dermal
injury. *p<0.05, **p<0.01
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4.4.

Discussion
In human dermal wounds fibrocytes appear as early as 4 days after injury, and

their number has been shown to increase substantially with wound age, peaking at
approximately 12-14 days21. As remodeling occurs, the number of fibrocytes in the
wound bed decreases21. However in hypertrophic scars, fibrocytes persist in high
numbers and are thought to promote overabundant collagen fiber deposition11.
Interestingly, levels of periostin expression also remain elevated in hypertrophic and
keloid scar tissue22. We previously demonstrated that loss of periostin expression reduces
fibrocyte infiltration into dermal scars, making periostin a potential therapeutic target for
the treatment of fibrotic pathologies associated with elevated fibrocyte levels.
On the opposite end of the spectrum, periostin expression and fibrocyte
infiltration have also been shown to independently promote wound closure. Periostin
upregulation enhances wound contraction by increasing α-SMA expression in the wound
bed. Infiltrating fibrocytes also have the ability to promote wound contraction by
differentiating into myofibroblast-like cells and by secreting molecular effectors that
stimulate the myofibroblastic differentiation of resident fibroblasts. To establish whether
periostin expression enhances fibrocyte participation in early stages of wound repair, we
measured fibrocyte levels in Pstn −/− and WT wounds at 4 and 7 days after dermal
injury. Periostin gene deletion did not alter the number of resident fibroblasts present in
dermal wounds at either time point. However at 7 days, WT wounds were found to
contain a significantly higher percentage of fibrocytes than Pstn −/− wounds.
Interestingly, the expression of periostin and α-SMA in the reparative ECM also peaks at
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this time point. These results correspond with our previous findings in 21-day dermal
wounds and also indicate that periostin expression may promote wound closure by
increasing the number of fibrocytes that participate in early dermal repair. Though a
specific mechanism for this change has not been identified, our results suggest that
periostin expression may either promote fibrocyte differentiation within the wound bed or
increase the number of fibrocytes that migrate into injured dermal tissue. Other
investigators have previously suggested that periostin functions as a profibrogenic
mediator, promoting the differentiation of mesenchymal progenitor cells into cardiac
fibroblasts and the maturation of dermal fibroblasts into myofibroblasts23,24. Through
integrin-mediated cell adhesion, periostin has also been shown to enhance the migratory
ability of several cell types, including ovarian epithelial cells, cushion mesenchymal
cells, and vascular smooth muscle cells25-27.
We measured the number of fibrocytes present in the bone marrow and peripheral
blood of Pstn −/− and WT mice before and after dermal injury to determine whether
periostin expression also influences fibrocyte behavior outside of the dermal wound bed.
In contrast to our observations in skin biopsies, excisional dermal wounding did not elicit
an increase in the number of fibrocytes in the bone marrow of either Pstn −/− or WT
mice. Similarly, the percentage of fibrocytes was also unaffected by periostin gene
deletion. Because dermal injury did not induce any changes in fibrocyte number, it is
difficult to determine whether or not injury-induced periostin expression affects the
formation of fibrocytes in the bone marrow. For future studies, we recommend
combining the use of Pstn −/− mice with the model of bleomycin-induced pulmonary
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fibrosis described by Phillips et al., in which bleomycin treatment was observed to
significantly increase the number of bone marrow fibrocytes10. Because periostin is
rapidly upregulated in bleomycin-treated mice, comparing the number of fibrocytes in the
bone marrow of Pstn −/− and WT mice after bleomycin-treatment would provide
valuable information regarding how periostin expression influences fibrocyte formation
in the bone marrow28.
In the peripheral blood, we observed a significant increase in the number of
fibrocytes present after dermal injury. The percentage of circulating fibrocytes in both
Pstn −/− and WT mice peaked at 4 days after injury and decreased gradually before
returning to basal levels at 11 days. Elevated numbers of circulating fibrocytes have been
found in patients with various fibrotic disorders10,12,14-17. To our knowledge however, this
is the first study to demonstrate that dermal injury significantly increases fibrocytes levels
in the peripheral blood. This suggests that injury-induced factors like periostin influence
fibrocyte behavior in the circulation, rather than only at sites of dermal injury, and that
the peripheral circulation may be a significant source of fibrocytes that invade injured
dermal tissue.
We also observed the percentage of fibrocytes in the peripheral blood to be
significantly lower in Pstn −/− mice compared to WT mice after dermal injury. At 4 and
7 days after injury, periostin gene deletion reduced the number of fibrocytes in the
peripheral blood by over fifty and seventy-five percent, respectively. These results
indicate that periostin expression promotes the injury-induced increase in circulating
fibrocytes, likely by one or more of the following mechanisms: increasing the formation
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of fibrocyte precursors in the bone marrow, promoting the mobilization of fibrocytes and
their precursors from the bone marrow into the peripheral circulation, and/or stimulating
the differentiation of fibrocytes in the peripheral blood. Increased numbers of fibrocytes
in the peripheral blood may contribute to the higher numbers of fibrocytes we observed in
the wound beds of WT mice compared to Pstn −/− mice.
Interestingly, Naik et al. recently demonstrated that fibrocytes and monocytes of
patients with pulmonary fibrosis produce higher levels of periostin in the peripheral blood
relative to healthy controls. They also showed that, in addition to structural sources of
periostin, hematopoietic cell-derived periostin promotes injury-induced fibrosis in the
lungs28. Further studies examining whether periostin is expressed by circulating cells
after dermal injury and, if so, how this source of periostin affects fibrocyte numbers in
the peripheral blood and skin would provide valuable information regarding the
mechanisms that govern fibrocyte differentiation and migration after dermal injury.
Collectively, our results indicate that regulation of fibrocyte behavior by injuryinduced periostin expression is likely to occur at multiple stages, involving fibrocytes and
their precursors in the bone marrow, peripheral circulation, and dermal wound bed. While
our findings do not demonstrate modulation of fibrocyte levels to be the sole mechanism
by which periostin gene deletion delays wound closure and reduces collagen content in
the dermal wound bed, they do clearly indicate that abrogation of periostin expression
can be used to reduce fibrocyte contribution to both early and late phases of dermal
wound repair.
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4.5.

Conclusions
Investigators have previously established that fibrocyte infiltration can contribute

to both timely dermal wound repair as well as excessive scar formation. These
observations have motivated additional research exploring factors that modulate fibrocyte
behavior for the development of therapeutics aimed at either stimulating wound closure
or reducing tissue fibrosis. In this chapter we demonstrate, for the first time, that periostin
expression significantly enhances fibrocyte levels in both the skin and peripheral blood at
early stages of wound repair. In combination with the results described in Chapter 3,
these findings contribute significantly to our understanding of fibrocyte biology by
establishing periostin to be an effector of fibrocyte levels at both early and late stages of
dermal repair. Our results also demonstrate that periostin expression influences fibrocyte
levels outside of the dermal wound bed, which raises questions regarding the effects of
hematopoietic and structural sources of periostin on fibrocyte behavior.

4.6.
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CHAPTER FIVE
PERIOSTIN EXPRESSION PROMOTES FIBROCYTE ADHESION AND
MIGRATION IN RESPONSE TO THE CXCL14/CXCR4 SIGNALLING AXIS
5.1

Introduction
The mobilization, homing, and engraftment of HSCs and their leukocyte

subpopulations involve a complex profile of adhesion molecules, chemoattractant
cytokines, and chemokine receptors. Recent work in the area of chemokine-chemokine
receptor interactions suggests that there is substantial overlap between the mechanisms
that govern these processes and fibrocyte migration1. Human fibrocytes express several
chemokine receptors, including CCR3, CCR5, CCR7, and CXCR4, and murine
fibrocytes express CCR2, CCR7, and CXCR42-4. The chemokine receptor CXCR4 and its
conjugate ligand stromal-derived factor 1 (CXCL12) play a critical role in HSC retention
in the bone marrow and also in HSC homing to sites of tissue injury5. Consistent with
their bone marrow origin, fibrocytes expressing CXCR4 have been shown to migrate in
response to a CXCL12 gradient4. CXCL12 secretion is associated with tissue damage
caused by events such as excisional and thermal burn injuries to the skin, pulmonary
fibrosis, and myocardial infarction4,6-10. The CXCR4/CXCL12 signaling axis has been
shown to promote pulmonary fibrosis by increasing fibrocyte infiltration into the lungs
and to enhance wound healing through the recruitment of bone marrow-derived
mesenchymal stem cells into dermal excisional and burn wounds4,6,7.
In Chapter 4, we described our findings that periostin expression contributes to
the elevated number of fibrocytes present in the peripheral blood and skin after dermal
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injury. These results suggest that periostin expression affects fibrocyte behavior at
multiple stages, potentially influencing fibrocytes and their bone marrow-derived
precursors in the bone marrow, peripheral circulation, and dermal wound bed. Other
investigators have previously demonstrated that periostin expression enhances the
migratory ability of several cell types11-13. In this study, we examined how periostin
expression specifically affects fibrocyte migration in response to the CXCR4/CXCL12
signaling axis. Using in vitro methods, we demonstrated that periostin gene deletion
significantly reduces bone marrow fibrocyte (BM fibrocyte) chemotaxis and integrinmediated migration. Subsequent in vivo assays revealed that loss of periostin also reduces
the number of circulating CXCR4+/Col I+ fibrocytes in mice after dermal injury.
Collectively, our findings suggest that periostin expression plays an important role in
fibrocyte trafficking in response to the CXCR4/CXCL12 signaling axis. Periostin gene
deletion may reduce the ability of fibrocytes to migrate from the bone marrow into the
peripheral circulation and then into skin after dermal injury, leading to the decrease in
fibrocyte numbers previously observed in the blood and skin of Pstn −/− mice.

5.2

Materials and Methods

5.2.1

Isolation and Culture of Bone Marrow Cells
Cells were harvested from the bone marrow of adult Pstn −/− and WT mice. Pstn

−/− mice were generated as described previously in Section 3.2.1. Mice were euthanized
by isofluorane inhalation followed by cervical dislocation. Using a 1 cc insulin syringe,
bone marrow cells were flushed from the femurs and tibiae with complete medium. Bone
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marrow cells in medium were aspirated through a 22-gauge needle and triturated several
times to generate a single cell suspension. The homogenized cell suspension was then
filtered through a 70 µm cell strainer, centrifuged at 1500 rpm for 5 minutes, and
resuspended in ice-cold FACS buffer. To separate hematopoietic cells from nonhematopoietic cells, bone marrow cells were labeled with PE-conjugated mouse-antimouse CD45 (BD Pharmingen) for 30 minutes at 4°C and sorted on a MoFlo Atrios cell
sorter using Summit v6.1 software. After sorting, CD45+ cells were washed and plated on
fibronectin-coated 24-well plates at 2.5x106 cells per well in complete medium. As
previously described, cells were cultured at 37°C, 5% CO2 for 12 days with regular
medium changes2.

5.2.2

Immunolabeling of Cultured Bone Marrow Cells
Cultured bone marrow cells were detached using TrypLE (Life Technologies) and

transferred to an 8-well chamber slide at a seeding density of 1.5x104 cells per well. After
24 hours of culture, cells were fixed in zinc formalin, permeabilized with Triton X-100,
and blocked with Background Buster. To determine whether they co-expressed
hematopoietic and mesenchymal markers, cultured bone marrow cells were incubated at
4°C overnight in diluted primary antibodies [goat anti-mouse CD45 and rabbit anticollagen type I (Rockland Immunochemicals Inc.)]. Primary antibodies were then
localized by incubation with coordinate secondary antibodies (Cy3-conjugated donkey
anti-goat IgG and Cy5-conjugated donkey anti-rabbit IgG) for one hour at room
temperature. Nuclear counterstaining was achieved with DAPI and slides were mounted
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in Fluoro-Gel. Cells were imaged at 20x magnification on a Leica DMI 4000B inverted
microscope (Leica Microsystems Inc.). Images were processed for qualitative analysis
using Adobe Photoshop CS5 software.

5.2.3

Chemotaxis of Bone Marrow Fibrocytes
The migration of BM fibrocytes was assessed in vitro using the Neuro Probe

ChemoTx System (Neuro Probe, Gaithersburg, MD) with a 5 µm pore-size polycarbonate
filter. After 12 days of culture, Pstn −/− and WT BM fibrocytes were detached using
TrypLE and allowed to recover for 45 minutes in complete medium at 37°C. Cells were
then suspended in migration medium [serum-free DMEM with 2% bovine serum albumin
(BSA)] at 6x105 cells/ml. A quantity of 50 µl of cell suspension was pipetted onto the
filter site above each well (Figure 5.1). Cells were allowed to migrate to lower wells
containing migration medium in the presence or absence of the chemoattractant CXCL12
(100 ng/ml, R&D Systems) for three hours at 37°C. Filter sites were fixed in methanol,
stained with DAPI, and mounted on glass slides in Fluoro-gel. The cells that migrated to
the lower side of the filter were imaged in 10 fields per filter site at 20x magnification
using a Leica DMI 4000B inverted microscope and counted using ImageJ software. A
minimum of four filter sites per condition was evaluated.
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Cell suspension
Polycarbonate membrane
Migration medium

3 hour incubation at 37°C

Figure 5.1 Use of the Neuro Probe ChemoTx system to study BM fibrocyte migration.
BM fibrocytes in suspension were pipetted onto each filter site and allowed to migrate
toward the lower chambers, which contained migration medium in the presence or
absence of the chemoattractant CXCL12.
5.2.4

Bone Marrow Fibrocyte Adhesion
The adhesion of BM fibrocytes to immobilized periostin and fibronectin was

quantified using previously published methods with modifications12. Wells of a roundbottom 96-well plate were coated with recombinant murine-derived periostin (20 µg/ml,
R&D Systems) or bovine-derived fibronectin (3 µg/ml, Sigma Aldrich) for one hour at
room temperature and then blocked with 1% BSA for one hour. After 12 days of culture
as described in Section 5.2.1, Pstn −/− and WT BM fibrocytes were detached using
TrypLE and allowed to recover for 30 minutes in complete medium at 37°C. Cells were
centrifuged and resuspended in serum-free DMEM, added to coated wells (30,000 cells in
100 µl per well), and allowed to adhere for one hour at 37°C. Round-bottom 96-well
plates were washed in warm PBS and the remaining adherent cells were fixed and stained
in 10% ethanol/2% crystal violet for 5 minutes. After washing out unbound dye, bound
crystal violet was solubilized by adding 0.1M sodium acetate in 50% ethanol. A
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spectrophotometer was used to record the absorbance at 560 nm of 9 wells per condition.

5.2.5

Integrin-mediated Migration of Bone Marrow Fibrocytes
The migration of BM fibrocytes on periostin and fibronectin-coated filters was

evaluated using the methods described in Section 5.2.3. Polycarbonate filters were coated
for one hour per side at 37°C with recombinant murine-derived periostin (10 µg/ml) or
bovine-derived fibronectin (3 µg/ml). Coated filters were allowed to dry at 4°C overnight
prior to use. A minimum of four filter sites for each condition was evaluated.
Additionally, function blocking antibodies against αv, β1, and β3 integrins
(Biolegend, San Diego, CA) were used to target integrin receptors involved in BM
fibrocyte migration on periostin and fibronectin-coated filters. After detachment with
TrypLE and 45 minutes of recovery in complete medium, Pstn −/− and WT BM
fibrocytes were incubated for 30 minutes at 4°C in migration medium containing function
blocking antibodies at 25ug/ml. Control cells were incubated without the addition of
function blocking antibodies. Migration assays were then conducted as previously
described using periostin and fibronectin-coated filters. Three filters sites per condition
were evaluated. The fold change was calculated for each condition (no blocking antibody,
anti-αv antibody, anti-β1 antibody, and anti-β3 antibody), where:

Fold  change =

#  cells  that  migrate  in  response  to  CXCL12  for  each  condition
#  cells  that  randomly  migrate  (no  CXCL12  and  no  blocking  antibodies)

A fold change of one indicates that the anti-integrin antibody used completely blocks
CXCL12-induced migration so that only random migration occurs.
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5.2.6

Flow cytometry analysis of circulating CXCR4+ fibrocytes
To detect circulating CXCR4+ fibrocytes in vivo, peripheral blood cells were

analyzed for co-expression of CXCR4 and collagen type I by flow cytometry using the
methods described in Sections 4.2.4 and 4.2.5. Nucleated cells were isolated from the
peripheral blood of Pstn −/− and WT mice before and 4 and 7 days after dermal injury.
Briefly, cells were labeled with phycoerythrin-conjugated (PE) CXCR4 (BD Biosciences)
at 4°C for 40 minutes. After fixation and permeabilization, cells were incubated with
rabbit anti-collagen type I (Rockland Immunochemicals Inc.) for 30 minutes at 4°C and
labeled with FITC-conjugated donkey anti-rabbit IgG. A minimum of 10,000 cells was
analyzed for each condition on a MoFlo Atrios cell sorter using Summit v6.1 software.
The average percentage of CXCR4+/Col I+ cells was calculated for each time point and
genotype. Data was analyzed using a Student’s t-test for independent samples, where pvalues <0.05 were considered significant.

5.3
5.3.1

Results
In vitro fibroblastic differentiation of bone marrow-derived cells
Fibrocytes can be identified by the co-expression of a hematopoietic marker

(CD45, CD34) and a mesenchymal marker (collagen type I, vimentin)14-16. Methods
employed for the isolation, growth, and characterization of fibrocytes commonly rely on
the derivation of fibrocytes from mononuclear cells in the peripheral blood2,17. Generally,
Ficoll-Paque density-gradient centrifugation is conducted to remove red blood cells from
the leukocyte-rich buffy coat fraction. Cells in the buffy coat fraction are then plated and
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cultured in DMEM supplemented with serum for 10-14 days. Over time non-adherent
cells are washed off through medium changes and fibrocytes appear as clusters of
spindle-shaped cells.
Given our lab’s focus on the bone marrow contribution of fibroblast-like cells to
tissue repair, we chose to isolate and culture hematopoietic cells from the bone marrow
rather than the peripheral blood18. Bone marrow cells were aspirated from the femurs and
tibiae of Pstn −/− and WT mice. To remove non-hematopoietic cells, bone marrow cells
were labeled and sorted for CD45 expression using flow cytometry. CD45+ cells were
then cultured for 12 days in complete medium. As with cultured peripheral blood
fibrocytes, adherent bone marrow cells adopted a fibroblast-like spindle-shaped
morphology (Figure 5.2, A and B). Cultured bone marrow cells were also confirmed to
co-express CD45 and collagen type I, as indicated by fluorescence microscopy (Figure
5.2, C, D, and E). Collectively, these observations demonstrate the ability of
hematopoietic bone marrow precursors to differentiate into fibrocytes in vitro.
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A

Pstn −/−

B

WT

C

Pstn −/−

D

WT

E

Negative control

Figure 5.2 Hematopoietic bone marrow-derived cells differentiate into fibrocytes in vitro.
A and B) Phase contrast images show that after 12 days of culture Pstn −/− and WT bone
marrow cells exhibit a fibroblast-like spindle-shaped morphology. C and D) Cultured
bone marrow cells co-express CD45 (red) and collagen type I (green). DAPI stained
nuclei are blue. E) Negative control samples incubated with only secondary antibodies
confirm specific labeling by primary antibodies against CD45 and collagen type I.
5.3.2

Bone marrow fibrocyte chemotaxis in response to CXCL12
Fibrocytes derived from peripheral blood mononuclear cells have previously been

shown to migrate in response to the CXCR4/CXCL12 signaling axis4. We performed
chemotaxis assays on polycarbonate filters to confirm that BM fibrocytes also migrate in
the presence of a CXCL12 gradient and to determine whether periostin gene deletion
affects their migration. We observed significant chemotaxis of Pstn −/− and WT BM
fibrocytes toward wells containing CXCL12 compared to controls with no added
chemoattractant (p=0.007 and p=0.010, respectively, Figure 5.3). Interestingly, periostin
gene deletion also was found to significantly reduce BM fibrocyte migration, with an
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average of 1337 WT cells counted per filter versus only 742 Pstn −/− cells counted per
filter (p=0.004, Figure 5.3).
Chemotaxis of BM fibrocytes
on polycarbonate filters

**
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Cells counted per filter

1600
1400

**

WT
Pstn -/-

1200
1000
800
600
400
200
0
no chemoattractant

CXCL12

Figure 5.3 Chemotaxis of BM fibrocytes in response to CXCL12 (100 ng/ml). The
presence of a CXCL12 gradient stimulated Pstn −/− and WT BM fibrocyte migration
across polycarbonate filters. Periostin gene deletion significantly reduced CXCL12induced BM fibrocyte migration. **p<0.01, n=8.
5.3.3

Adhesion of bone marrow fibrocytes
Cell migration relies not only on the expression of paracrine chemokines such as

CXCL12, but also on interactions between cell integrin receptors and various components
of the surrounding ECM. To determine whether periostin gene deletion alters fibrocyte
interactions with the ECM, we quantified differences in BM fibrocyte adhesion to
immobilized periostin and fibronectin, two adhesion proteins that are abundantly
expressed in the ECM during dermal repair. WT BM fibrocytes exhibited a significantly
greater ability to adhere to both periostin and fibronectin-coated wells compared to Pstn
−/− BM fibrocytes (p=0.044 and p=0.001, respectively, Figure 5.4).
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Fibronectin

Periostin

Coating

Figure 5.4 BM fibrocyte adhesion to immobilized periostin and fibronectin. Pstn −/− cells
exhibit a reduced ability to adhere to periostin and fibronectin relative to WT cells.
*p<0.05, **p<0.01, n=9.
5.3.4

Integrin-mediated migration of bone marrow fibrocytes
We also examined whether periostin gene deletion affects integrin-mediated

migration of BM fibrocytes. Chemotaxis assays were performed using polycarbonate
filters coated with either periostin or fibronectin. No significant differences in migratory
behavior were observed between Pstn −/− and WT BM fibrocytes on fibronectin-coated
filters (Figure 5.5, A). In contrast, on periostin-coated filters significantly fewer Pstn −/−
BM fibrocytes migrated randomly and in response to the CXCL12 gradient (p=0.017
without chemoattractant and p=0.005 with added CXCL12, Figure 5.5, B). Of note,
random migration of WT cells was also significantly higher on periostin-coated filters
than on uncoated polycarbonate filters, with an average of 551 WT cells counted on
periostin-coated filters and only 140 WT cells counted on uncoated filters (p=0.009,
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Figures 5.3 and 5.5, B). Coating filters with periostin did not increase the random
migration of Pstn −/− BM fibrocytes (p=0.485, Figures 5.3 and 5.5, A).

A

B
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on periostin-coated filters
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Figure 5.5 Chemotaxis of cultured BM fibrocytes on periostin and fibronectin-coated
filters. A) Pstn −/− cells exhibit reduced migration on periostin-coated filters with and
without the presence of a CXCL12 gradient. *p<0.05, **p<0.01, n=5. B) On fibronectincoated filters, no significant differences are observed between Pstn −/− and WT cells.
n=4.
Periostin contains four Fas-1 domains that, in addition to binding proteins such as
TNC and BMP-1, promote integrin-dependent cell adhesion and motility by serving as
ligands for various integrin receptors. To identify integrin receptors on BM fibrocytes
that interact with periostin during chemotaxis, cells were incubated with function
blocking antibodies against αv, β1, and β3 integrin subunits. Periostin has been previously
shown to interact directly with integrins containing these subunits11,12. Blocking
antibodies against αv and β1 subunits were found to significantly inhibit the chemotactic
migration of BM fibrocytes on periostin, reducing the fold change from 2.60 to 1.32 and
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1.26 for Pstn −/− cells and from 2.32 to 1.11 and 1.10 for WT cells, respectively (p<0.05
for all conditions, Figure 5.6).

Inhibition of chemotaxis by anti-integrin antibodies
on periostin-coated filters
4

*

*
WT

Fold change

3

Pstn -/-

2

1

0
no blocking
antibody

anti-αv

anti-β1

anti-β3

Figure 5.6 Inhibition of BM fibrocyte migration on periostin-coated filters with integrin
blocking antibodies. Antibodies against αv and β1 integrin receptors significantly reduced
the chemotactic migration of BM fibrocytes on periostin. *p<0.05, n=3.
Fibronectin is an adhesive protein that is also highly expressed during early stages
of wound repair. BM fibrocytes were incubated with function blocking antibodies against
αv, β1, and β3 integrin subunits to determine whether they also play a critical role in
CXCL12-induced fibrocyte migration on fibronectin. Unique from periostin, antibodies
against β1 and β3 integrin subunits were found to significantly inhibit the chemotactic
migration of BM fibrocytes on fibronectin, reducing the fold change from 1.82 to 0.94
and 1.34 for Pstn −/− cells and from 2.14 to 1.24 and 1.55 for WT cells, respectively
(Figure 5.7, p<0.05 for all conditions).
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Inhibition of chemotaxis by anti-integrin antibodies
on fibronectin-coated filters
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Figure 5.7 Inhibition of BM fibrocyte migration on fibronectin-coated filters with integrin
blocking antibodies. Antibodies against β1 and β3 integrin receptors significantly reduced
the chemotactic migration of BM fibrocytes on fibronectin. *p<0.05, n=4.
5.3.5

Quantification of CXCR4+ fibrocytes in the peripheral blood
To determine whether periostin expression influences fibrocyte participation in

the CXCR4/CXCL12 signaling axis in vivo, we used flow cytometry to measure the
number of circulating CXCR4+/Col I+ fibrocytes in Pstn −/− and WT mice before and 4
and 7 days after dermal injury. Though not traditionally used as a hematopoietic marker
for fibrocytes, investigators agree that CXCR4 is a hematopoietic cell marker and have
previously used dual expression of CXCR4 and collagen type I to identify fibrocytes in
the peripheral blood15. Representative 2D plots of labeled peripheral blood cells are
shown in Figure 5.8, with CXCR4+/Col I+ cells located in region R11.
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WT

4 days

0 days

Pstn −/−

Figure 5.8 CXCR4+/Col I+ fibrocyte subsets in the peripheral blood of Pstn −/− and WT
mice before and 4 days after injury (R11). Representative histograms show a visible
increase in the percentage of CXCR4+/Col I+ cells after dermal wounding in Pstn −/− and
WT mice.
These 2D plots were used to calculate the average percentage of CXCR4+/Col I+
fibrocytes in the peripheral blood of Pstn −/− and WT mice at each time point. Dermal
injury was observed to induce a significant increase in the number of circulating
CXCR4+/Col I+ cells in both Pstn −/− and WT mice (Figure 5.9). The percentage of
circulating CXCR4+/Col I+ cells was highest at 4 days in both genotypes, increasing from
0.19% to 0.67% in Pstn −/− mice (p=0.187) and from 0.16% to 1.54% in WT mice
(p=0.007). Prior to dermal wounding, Pstn −/− and WT mice were observed to contain a
similar percentage of circulating CXCR4+/Col I+ cells. However, dermal injury induced a
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significantly higher increase in the number of circulating CXCR4+/Col I+ cells in WT
mice compared to Pstn −/− mice. At 4 days, CXCR4+/Col I+ cells comprised 1.54% of
cells in WT blood and only 0.67% of cells in Pstn −/− blood (p=0.026). Similarly, at 7
days CXCR4+/Col I+ cells comprised 0.55% of cells in WT blood and only 0.16% of cells
in Pstn −/− blood (p=0.003). These differences correspond with the results described in
Chapter 4, which show that CD45+/Col I+ fibrocyte levels also peak at 4 days after injury
and are significantly higher in the presence of periostin expression.
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0.2
0
0
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Days after injury

7

Figure 5.9 Quantification of CXCR4+/Col I+ cell levels in the peripheral blood of Pstn
−/− and WT mice before and after dermal injury. Periostin gene deletion significantly
reduced the percentage of circulating CXCR4+/Col I+ cells at 4 and 7 days after dermal
injury. *p<0.05, **p<0.01
5.4

Discussion
A growing body of research focused on the contribution of periostin to numerous

biological processes, such as wound healing, tissue fibrosis, and tumor metastasis, has
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shown that periostin expression influences many aspects of cell behavior, including cell
differentiation, proliferation, adhesion, and migration19-23. Our results described in
Chapters 3 and 4 demonstrate that periostin expression increases the number of
CD45+/Col I+ fibrocytes that contribute to dermal repair. Based on the diverse effects of
periostin on cell behavior, these results suggest that periostin expression promotes the
fibroblastic differentiation of bone marrow progenitors and/or increases the trafficking of
fibrocytes and their precursors into dermal wounds. To improve our understanding of
how periostin expression influences fibrocyte mobilization, homing, and engraftment to
sites of tissue injury, we studied the effects of periostin gene deletion on fibrocyte
adhesion and migration in vitro. Our findings demonstrate that periostin gene deletion
significantly reduces BM fibrocyte adhesion to periostin and fibronectin-coated surfaces.
Correspondingly, loss of periostin also reduces fibrocyte chemotaxis and integrinmediated migration in response to the CXCR4/CXCL12 signaling axis. These results
suggest that increased fibrocyte trafficking may be one mechanism by which periostin
expression promotes fibrocyte contribution to dermal repair.
Methods used to generate fibrocytes in vitro typically rely on the derivation of
fibrocytes from mononuclear cells in the peripheral blood2,17. However, recent
publications have identified fibrocytes in the bone marrow and have reported the
successful in vitro derivation of fibrocytes from bone marrow cells4,18,24,25. Scholten et al.
isolated CD45+collagen+ cells from the bone marrow using flow cytometry and, after 7
days of culture, observed these cells to give rise to classic collagen-expressing spindleshaped fibroblast-like cells25. Using a murine model of clonal engraftment of cells
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derived from a single EGFP+ HSC, Ebihara et al. also demonstrated that EGFP+ bone
marrow cells adopt a fibroblast-like phenotype and express mesenchymal markers in
culture18. Based on these publications, as well as our lab’s interest in the bone marrow
contribution of fibroblast-like cells to tissue repair, we chose to isolate and culture murine
fibrocytes from CD45+ bone marrow cells rather than nucleated peripheral blood cells.
As with peripheral blood fibrocyte cultures, within 12 days adherent bone marrow cells
adopted a fibroblast-like spindle-shaped morphology and were confirmed to co-express
CD45 and collagen type I through immunofluorescence microscopy. According to the
minimum criteria used to define fibrocytes of co-expression of hematopoietic and
mesenchymal markers, our observations demonstrate that hematopoietic bone marrow
cells have the ability to differentiate into fibrocytes in vitro.
The effects of periostin gene deletion on BM fibrocyte chemotaxis were studied
using the CXCR4/CXCL12 signaling axis. CXCR4 is widely expressed on hematopoietic
cells, including fibrocytes and their HSC and monocyte precursors26. CXCL12, which
binds the CXCR4 receptor and is an important chemoattractant for CXCR4+ cells, is
significantly upregulated in the peripheral blood and blister fluid of patients with skin
burns and at the margins of excisional dermal wounds9,27,28. Upregulation of CXCL12
expression in the peripheral blood and tissues in response to disease or injury has been
suggested to play a significant role in the mobilization of progenitor cells and fibrocytes
from the bone marrow26. In this study, a CXCL12 gradient was observed to induce Pstn
−/− and WT BM fibrocyte chemotaxis across porous polycarbonate filters. Interestingly
however, migration of WT cells was substantially greater than that of Pstn −/− cells. This
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suggests that periostin expression may increase the sensitivity of BM fibrocytes to
CXCL12, potentially by upregulating the expression of CXCR4 on BM fibrocytes in
vitro. CXCR4 upregulation on fibrocytes has been shown to be induced by hypoxia and
growth factors through the PI3-kinase/Akt/mTOR pathway26. Of note, periostin
expression has also been identified to activate the PI3-kinase/Akt pathway, inducing
collagen type I expression and promoting the proliferation of murine dermal fibroblasts in
vitro21,29. To our knowledge however, the influence of periostin expression on CXCR4
receptor upregulation has not been studied. Future work investigating this, as well as the
potential involvement of the PI3-kinase/Akt pathway in periostin-induced CXCR4
upregulation, would provide valuable information regarding the mechanisms that govern
fibrocyte homing to sites of tissue injury.
Adhesion molecules, namely integrins, also play a central role in cell trafficking.
Integrins are the major transmembrane receptors that mediate cellular interactions with
the ECM during cell migration. By linking the ECM to actomyosin filaments, integrinbased adhesions generate traction for cell movement and also organize signaling
networks that regulate cell migration, as well as other cellular processes including gene
expression, differentiation, proliferation and apoptosis30. Treatment of dermal fibroblasts
with exogenous periostin has been shown to increase the phosphorylation of integrinassociated signaling molecules, such as FAK, STAT3, Akt, and p44/42MAPK,
suggesting that interactions between periostin and cell-surface integrins activate key
signaling pathways involved in wound repair21,29.
In this study, we observed that periostin gene deletion significantly reduces BM
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fibrocyte adhesion to periostin and fibronectin, two ECM proteins expressed after dermal
injury that are also known to mediate cell migration. Based on these differences, we were
interested to determine whether Pstn −/− BM fibrocytes also exhibit reduced integrinmediated migration. We performed migration assays using periostin and fibronectincoated polycarbonate filters. Migration on both surfaces was mediated by integrinsubstrate interactions. Blocking antibodies against αv and β1 integrin subunits inhibited
CXCL12-induced BM fibrocyte migration on periostin, while antibodies against β1 and
β3 subunits inhibited migration on fibronectin. These findings highlight similarities
between integrin function on fibrocytes and on endogenous fibroblasts. Additionally, on
periostin-coated filters, periostin gene deletion was observed to significantly reduce both
random and CXCL12-induced migration of BM fibrocytes. These differences were not
observed on fibronectin-coated filters, suggesting changes in migratory behavior to be
substrate specific.
The adhesive and migratory behavior of cells is heavily affected by cell type and
integrin expression31. Our results suggest that periostin gene deletion alters the
transcriptome of BM fibrocytes in culture, potentially affecting integrin expression and/or
downstream signaling pathway activation. Further research investigating the influence of
periostin on integrin expression and the activation of integrin-associated signaling
molecules such as PI3-kinase will be important for understanding the mechanisms that
govern fibrocyte adhesion and migration. Such knowledge will assist in the development
of therapeutics aimed at modulating fibrocyte trafficking in vivo.
To supplement our in vitro findings with in vivo evidence of periostin’s influence
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on fibrocyte participation in the CXCR4/CXCL12 signaling axis, we also studied how
periostin gene deletion affects CXCR4+/Col I+ fibrocyte levels in the blood. Tourkina et
al. previously reported increased levels of both CD45+/Col I+ and CXCR4+/Col I+
fibrocytes in the peripheral blood of patients with systemic sclerosis15. CD45+/Col I+ cells
were found to be more prevalent than CXCR4+/Col I+ cells in this patient population. Our
results reflect a similar trend. Dermal injury increased the number of circulating
CXCR4+/Col I+ cells in both Pstn −/− and WT mice. CXCR4+/Col I+ fibrocytes levels
were also slightly lower than the CD45+/Col I+ fibrocyte levels reported in Chapter 4.
Most interestingly however, at 4 and 7 days after injury, a significantly greater
number of CXCR4+/Col I+ fibrocytes was observed in the peripheral blood of WT mice
compared to Pstn −/− mice. This suggests that injury-induced periostin expression may
increase circulating fibrocyte levels by stimulating the mobilization of CXCR4+
fibrocytes and their precursors from the bone marrow into the peripheral circulation or by
promoting the fibroblastic differentiation of CXCR4+ precursors in the peripheral blood.
Our in vitro data suggests that increased mobilization of fibrocytes and their precursors
from the bone marrow into the peripheral circulation may occur through two
mechanisms, including by enhanced sensitivity to injury-induced CXCL12 expression
through CXCR4 upregulation or by increased integrin-mediated migration through
altered expression of integrin receptors and/or activation of downstream signaling
pathways. Additional in vitro and in vivo studies that quantify the effects of periostin on
CXCR4 and integrin receptor expression as well as migration-related signaling pathway
activation must be performed to determine whether these mechanisms specifically

120

contribute to the higher CXCR4+/Col I+ fibrocyte levels observed in injured WT mice
relative to Pstn −/− mice.

5.5

Conclusions
The mechanisms that govern the mobilization, homing, and engraftment of

fibrocytes in response to tissue injury remain to be fully understood. However, in this
study we demonstrate a novel role for periostin in promoting fibrocyte adhesion and
migration. Using in vitro assays, we show that periostin gene deletion reduces BM
fibrocyte adhesion to both periostin and fibronectin and decreases integrin-mediated
migration on periostin, as well as CXCL12-induced chemotaxis. These results suggest
that periostin expression influences the transcriptome of fibrocytes in culture, potentially
altering integrin and chemokine receptor expression and migration-related signaling
pathway activation. Such changes could reduce the mobilization of fibrocytes and their
precursors from the bone marrow into the peripheral circulation and decrease their
infiltration into dermal wounds. We also present in vivo data that supports our in vitro
findings and suggests that periostin expression positively influences fibrocyte
participation the CXCL4/CXCL12 signaling axis. While periostin expression likely
affects fibrocyte behavior through multiple mechanisms, our data provides original
evidence suggesting that periostin plays a significant role in fibrocyte trafficking after
dermal injury.
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CHAPTER SIX
CONCLUSIONS
Dermal wound repair is a complex process guided by a dynamic interplay
between various cell types and the surrounding extracellular environment. Understanding
this interplay is important for designing effective therapies that promote the closure of
non-healing wounds and prevent excessive scar formation. Periostin expression and bone
marrow-derived fibrocyte infiltration have been shown by other investigators to
independently contribute to dermal wound closure and tissue fibrosis. However, to our
knowledge, the relationship between these components in the context of dermal repair
has not been investigated. The present work demonstrates a novel role for periostin in
promoting fibrocyte contribution to dermal wound healing and also suggests that
therapeutic strategies aimed at modulating injury-induced periostin expression may be
effective in controlling fibrocyte contribution to wound closure and tissue fibrosis.

6.1

Summary of Key Findings
The overall objective of this project was to identify how periostin expression

influences fibrocyte behavior in response to dermal injury. Based on an extensive review
of the literature, we hypothesized that injury-induced periostin expression enhances
fibrocyte contribution to dermal wound closure and scar formation. The following three
aims were used to study this hypothesis: (I) identify the effects of periostin expression on
the composition and structural organization of the reparative ECM after dermal injury,
(II) determine the effects of periostin expression on fibrocyte levels after dermal injury,
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and (III) establish the effects of periostin expression on fibrocyte trafficking. In this
section, we will summarize the conclusions we have drawn from this project as they
apply to these aims and the overall project objective.
Several independent studies previously demonstrated that periostin gene deletion
delays dermal wound closure, suggesting that exogenous application of periostin protein
may be useful for the treatment of non-healing lesions1-3. However, despite its elevated
expression in dermal fibroproliferative disorders, the influence of periostin on the
composition and architecture of the reparative ECM in dermal wounds has not been
previously examined. In Chapter 3, we showed for the first time that loss of periostin
most significantly alters scar tissue composition by reducing thick collagen fiber content
at late stages of wound remodeling. Interestingly, periostin gene deletion has also been
shown to reduce collagen accumulation in mice after myocardial infarction and
bleomycin-induced pulmonary fibrosis, two fibrotic pathologies associated with
significant levels of fibrocyte infiltration4,5. Subsequent quantification of CD45+/Col I+
fibrocytes through immunofluorescence labeling revealed that periostin gene deletion
also reduces fibrocyte levels in dermal wounds at late stages of repair. Fibrocytes
represent an additional source of collagen in dermal wounds. They also secrete numerous
cytokines, chemokines, and growth factors that have been suggested to regulate resident
fibroblast activity by promoting migration, proliferation, and collagen production6.
Together, these results suggest that injury-induced periostin expression may promote
collagen accumulation in dermal scar tissue by increasing fibrocyte participation in late
stages of dermal wound repair.
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In addition to promoting tissue fibrosis, infiltrating fibrocytes have the ability to
facilitate wound closure by differentiating into myofibroblast-like cells that participate
directly in wound contraction and by secreting molecular effectors that promote the
myofibroblastic differentiation of resident fibroblasts6,7. In Chapter 4 we examined
whether periostin expression also increases CD45+/Col I+ fibrocyte levels in dermal
wounds at early stages of repair, specifically during the wound contraction period. Using
flow cytometry, we observed fibrocyte levels in dermal wounds to be significantly higher
in WT mice than in Pstn −/− mice at 7 days after injury. Interestingly, the expression of
periostin and α-SMA also peaks at this time point. These results suggest that, in addition
to promoting collagen accumulation in mature wounds, periostin expression may also
stimulate wound closure by increasing the number of fibrocytes present in dermal
wounds at early stages of repair.
To study fibrocyte behavior outside of the dermal wound bed, we also measured
CD45+/Col I+ fibrocyte levels in the bone marrow and peripheral blood before and after
dermal injury. Dermal wounding did not increase bone marrow fibrocytes levels,
indicating that factors produced in response to dermal injury do not significantly affect
fibrocyte formation in the bone marrow. In the peripheral blood however, fibrocyte levels
were significantly elevated, as has been previously observed in human patients with
various fibrotic disorders. To our knowledge, this is the first time that excisional dermal
wounding has been shown to stimulate an increase in circulating fibrocyte levels. In
addition to demonstrating that dermal injury-induced factors influence fibrocyte behavior
in the blood, these results also suggest that the circulation may be a significant source of

127

fibrocytes that infiltrate dermal wounds. In response to these observations, we studied
how dermal injury-induced periostin expression specifically affects circulating fibrocyte
levels. As observed previously in the dermal wound bed, we found that periostin
expression also elevates fibrocyte levels in the peripheral blood. This demonstrates that
periostin influences fibrocyte behavior beyond the site of tissue injury and raises
important questions regarding the impact of structural and hematopoietic sources of
periostin on fibrocyte behavior.
Collectively, the results described in Chapters 3 and 4 suggest a novel role for
periostin in modulating fibrocyte behavior at both early and late stages of dermal repair
and in multiple locations, including in the peripheral blood and dermal wound bed.
Periostin expression may enhance the injury-induced increase in fibrocyte levels in the
peripheral blood and dermal wound bed by promoting the fibroblastic differentiation of
fibrocyte precursors and/or increasing the trafficking of fibrocytes and their precursors
into these tissues. These possible mechanisms, which will be discussed in greater detail in
Section 6.2, are supported by the findings of other investigators that show periostin
expression to promote (myo)fibroblastic cell differentiation as well as cell adhesion and
migration.
The mobilization, homing, and engraftment of fibrocytes after tissue injury is
critical for their participation in wound repair and fibrosis. In Chapter 5, we compared the
migratory ability of Pstn −/− and WT BM fibrocytes to determine whether fibrocyte
trafficking is influenced by periostin expression. Using in vitro migration assays, we
demonstrated that periostin gene deletion reduces CXCL12-induced chemotaxis and
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integrin-mediated migration on periostin coated filters. These results suggest that
periostin expression alters the transcriptome of BM fibrocytes in vitro, potentially
reducing the expression of chemokine and integrin receptors, as well as the activation of
migration-related signaling pathways. These changes could reduce the mobilization of
fibrocytes from the bone marrow into the peripheral circulation and decrease their
infiltration into dermal wounds, leading to the lower fibrocyte levels observed in Pstn −/−
mice as reported in Chapters 3 and 4. We also presented data showing that periostin gene
deletion reduces the number of CXCR4+/Col I+ fibrocytes in the peripheral blood. This
supports our in vitro findings and indicates that periostin expression has a positive
influence on fibrocyte participation in the CXCR4/CXCL12 signaling axis in vivo.
Together, the results presented in Chapter 5 provide evidence that periostin plays an
important role in fibrocyte trafficking and suggest that loss of periostin expression may
reduce fibrocyte levels by decreasing their migratory ability.
Collectively, the clinical and scientific implications of the work presented in this
dissertation are quite significant. For the first time, we demonstrate that injury-induced
periostin expression positively influences fibrocyte behavior after dermal injury, as
observed through increased fibrocyte levels in the peripheral blood and skin and
increased fibrocyte migration in vitro. Other investigators have shown periostin
expression and fibrocyte infiltration to individually promote wound closure and tissue
fibrosis. In this work however, by relating periostin protein function to fibrocyte
behavior, we provide original evidence suggesting that modulation of periostin
expression can be used to control fibrocyte contribution to wound repair and fibrosis.
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Because of the substantial burden that wound healing complications place on our
healthcare system, this is a very exciting scientific discovery that represents a significant
advancement in our understanding of how the extracellular environment influences cell
function during tissue repair. This work also provides a foundation for future scientific
research to explore the relationship between periostin expression and fibrocyte behavior
in other organ systems, particularly those affected by severe tissue fibrosis.

6.2

Suggested Mechanisms
The present work raises important questions regarding the specific mechanisms

by which periostin expression increases fibrocyte levels in the peripheral blood and skin
after excisional dermal wounding. Based on a review of the current literature and the
results presented in Chapters 3, 4, and 5, we propose the increase in fibrocyte levels to
result from increased fibroblastic differentiation of fibrocyte precursors and/or increased
trafficking of fibrocytes and their precursors. The schematic shown in Figure 6.1 outlines
these mechanisms.
In 2006, Visconti et al. proposed the “periostin hypothesis,” which suggests that
periostin promotes and maintains the fibroblastic differentiation of cells and/or inhibits
their differentiation into other mesenchymal lineages8. Research examining this function
of periostin has focused primarily on cardiac development and repair, with periostin
having been shown to direct the fibroblastic differentiation and collagen secretion of
cardiac mesenchymal progenitor cells4,9. More recently, periostin expression has been
shown to promote myofibroblastic differentiation in dermal wounds, leading to enhanced
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wound closure2. The results presented in this dissertation suggest that periostin may also
enhance the fibroblastic differentiation of bone marrow progenitor cells, as evidenced by
increased fibrocyte levels in the peripheral blood and dermal wound bed of WT mice
relative to Pstn −/− mice. To further test whether periostin is an active effector of
fibroblastic differentiation in fibrocyte precursors, we recommended quantifying
fibroblast-specific mRNA and protein expression in cultured BM fibrocytes and in
fibrocytes and their CD14+ mononuclear precursors isolated from the peripheral blood
and skin of WT and Pstn −/− mice after dermal injury.
The results described in Chapter 5 suggest that periostin expression also
influences fibrocyte trafficking, specifically by increasing fibrocyte migration in response
to the CXCR4/CXCL12 signaling axis. Such changes could increase the mobilization of
fibrocytes and their precursors from the bone marrow into the peripheral blood and/or
their infiltration into the wound bed after dermal injury. This would lead to the higher
fibrocyte levels observed in the blood and skin of WT mice compared to Pstn −/− mice.
Other studies have previously reported periostin expression to promote cell motility,
namely

through

increased

integrin-mediated

activation

of

various

signaling

pathways3,10,11. Additional insights into the possible role of periostin in promoting the
trafficking of fibrocytes and their precursors could be provided by examining the
phosphorylation of key signaling molecules such as FAK, Akt, and PI3-kinase in cultured
BM fibrocytes and in fibrocytes and their CD14+ mononuclear precursors isolated from
murine bone marrow, peripheral blood, and dermal wounds after injury. In addition to
activating migration-related signaling pathways, our results suggest that periostin may
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upregulate chemokine and integrin receptor expression on fibrocytes. Therefore, we also
recommend quantifying the expression of the chemokine receptor CXCR4 and integrin
receptor subunits αv, β1, and β3 on cultured BM fibrocytes as well as murine fibrocytes
and their CD14+ mononuclear precursors in vivo. Such work would help to further
elucidate the role that periostin plays in fibrocyte homing to dermal wounds.

Bone Marrow

Peripheral Blood

Dermal Wound

Increased
differentiation

Increased
mobilization

Increased
differentiation

Increased
infiltration

Increased
infiltration

Figure 6.1 Schematic outlining potential mechanisms by which periostin expression
increases fibrocyte levels in the peripheral blood and skin after dermal injury. Blue cells:
fibrocyte precursors, Green cells: mature fibrocytes.
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6.3

Recommendations for Future Work
The work presented in this dissertation establishes a novel role for periostin in

modulating fibrocyte behavior in response to dermal injury and provides a foundation for
future studies aimed at controlling fibrocyte contribution to wound repair and tissue
fibrosis in the skin and other organs. Having shown a positive relationship between
periostin expression and fibrocyte levels, in addition to the work proposed in Section 6.2,
we now recommend the following future studies to further elucidate the mechanisms that
govern this relationship and to identify whether local modulation of periostin expression
may be used to control fibrocyte activity for therapeutic applications.

1. Examine how hematopoietic and structural sources of periostin influence fibrocyte
levels after dermal injury.
In a recent publication, Naik et al. showed that periostin levels are upregulated
in both the lungs and peripheral blood of patients with IPF5. Pulmonary fibroblasts
were observed to be the primary source of periostin in the lungs, while monocytes
and fibrocytes were found to produce periostin in the blood. Using chimeric mice,
Naik et al. established that both sources contribute to lung fibrosis. However, the
effect of each source on fibrocyte behavior was not specifically examined. We first
suggest quantifying periostin levels in the peripheral blood of injured WT mice to
determine whether excisional dermal injury also upregulates periostin expression in
the circulation. Then, to establish whether hematopoietic and/or structural sources of
periostin affect fibrocyte behavior, we recommend measuring fibrocyte levels in the
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peripheral blood and dermal wound bed of chimeric mice generated by
transplantation of WT or Pstn −/− bone marrow into WT or Pstn −/− recipients (Table
6.1)
Recipient

WT

Pstn −/−

WT

WT x WT
(control)

WT x Pstn −/−
(hematopoietic sources of
periostin)

Pstn −/−

Pstn −/− x WT
(structural sources of
periostin)

Pstn −/− x Pstn −/−
(control)

BM Donor

Table 6.1 Generation of chimeric mouse models to study the influence of
hematopoietic and structural sources of periostin on fibrocyte behavior.
2. Determine whether modulation of periostin expression can be used to control
fibrocyte contribution to wound closure and tissue fibrosis.
If structural sources of periostin (i.e. fibroblast-secreted periostin in the
granulation tissue) are observed to enhance infiltrating fibrocyte levels and promote
collagen accumulation in the dermal wound bed, we recommend conducting
additional studies to determine whether local modulation of periostin expression can
be used to control fibrocyte behavior for therapeutic applications. Recombinant
periostin protein can be delivered to increase periostin levels for delayed would repair
applications and a neutralizing antibody against periostin or silencing RNAs
(siRNAs) can be delivered to inhibit local expression of periostin for the reduction of
dermal scarring.
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To facilitate the clinical translation of this work, appropriate drug delivery
systems should be tested to optimize effective modulation of periostin expression in
dermal wounds. Delivery of periostin protein, neutralizing antibodies, and siRNAs
can be achieved through multiple approaches, which broadly include topical
application, intradermal injection, and incorporation into biodegradable scaffolds.
The rate of wound closure, collagen content in the granulation tissue, and fibrocyte
levels in the peripheral blood and skin should be measured to assess the efficacy of
each treatment method.

3. Study how periostin expression influences fibrocyte participation in wound closure in
hard-to-heal wounds and, at the opposite end of the spectrum, scarring in cases of
excessive dermal fibrosis.
The model of excisional dermal wound repair used in this project followed a
sequence of events associated with normal wound healing. However, dermal wounds
requiring advanced therapeutic treatments typically exhibit impairments in the
healing process that prevent timely wound closure and result in excessive tissue
fibrosis. Therefore, we also recommend examining the effects of periostin expression
on fibrocyte behavior in murine models characterized by delayed and fibrotic wound
healing to determine whether the relationship established in this dissertation holds
true in cases of impaired wound repair. Two specific murine models that we suggest
for these studies include excisional dermal injury in diabetic (db/db) mice and
bleomycin-induced skin fibrosis.
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4. Explore the relationship between periostin expression and fibrocyte levels in other
organ systems and pathologies
As discussed throughout this dissertation, periostin expression and fibrocyte
infiltration have been shown to individually contribute to tissue fibrosis in several
organs other than the skin. Given the devastating effects of excessive fibrosis in the
heart and lungs, as well as the clear contribution of these elements to cardiac and
pulmonary fibrogenesis, we recommend examining the relationship between periostin
expression and fibrocyte infiltration in these organs as well.

6.4
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